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THE IMPACT OF SHEAR RATE AND REVERSE FLOW ON CARDIAC MORPHOGENESIS AND GENE 
EXPRESSION IN THE EMBRYONIC ZEBRAFISH HEART 
 
 
Missteps in formation of the embryonic heart can have drastic consequences, making 
cardiac malformations a common human birth defect. During development, biomechanical 
factors including shear stress and reverse flow impact cardiogenesis. Shear stress is an 
epigenetic biomechanical force acting upon endothelial cells. Normally, a short period of 
reverse flow occurs prior to atrioventricular valve formation during ventricle systole and atrial 
diastole. The goal of our research is to investigate how altered biomechanical forces acting on 
endocardial cells lead to genetic responses by the heart. The mammalian zinc finger 
transcription factor Krüppel-like factor 2 (KLF2) responds to shear stress signals. Here, we 
explore the zebrafish KLF genes: klf2a, klf2b, and klf4. Whole embryo RT-PCR indicates that the 
three genes are expressed throughout early development, with cardiac expression in all genes 
present by 48 hours post fertilization. To evaluate how changes in biomechanical environments 
trigger altered gene expression in endocardial cells, we used comparative qPCR to quantify 
klf2a, klf2b, and klf4 expression levels in embryonic hearts with altered shear stress or reverse 
flow. Knockdown of the hematopoiesis gene gata2 was found to decrease blood viscosity, 
thereby decreasing both shear stress and reverse flow. Knockdown of contractility gene 
filaminCb was found to decrease shear stress but significantly increase reverse flow. Using high-
speed imaging we quantified these forces and correlated changes in klf2a, klf2b, and klf4 
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expression. klf2a expression levels decreased in response to changes in both blood viscosity 
and cardiac contractility. klf2b and klf4 expression levels did not significantly change with these 
changes in biomechanical stresses. Our investigations considered the impact of blood viscosity 
versus cardiac contractility on KLF expression and determined that klf2a is a flow response 
gene. This data confirms previous studies that klf2a is in fact a flow response gene and shows 
that klf2b and klf4 are not responsive to changes in blood viscosity or cardiac contractility. 
Future studies will use transcriptomic approaches to identify genes regulated by the KLF family 
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Zebrafish are a tropical freshwater fish used as a model organism for developmental 
genetics since the 1980s (Figure 1.1a) (Ackermann and Paw, 2003; Howe et al., 2013). 
Researchers are interested in zebrafish because of the significant homology between fish genes 
and human genes (Howe et al., 2013). Howe and colleagues identified that 71.4% of human 
genes are orthologous to at least one zebrafish gene (Howe et al., 2013). These researchers also 
noted that zebrafish have approximately two genes to each human gene, thought to be in part 
due to teleost-specific genome duplication (Meyer and Schartl, 1999; Howe et al., 2013). This 
genome duplication occurred after the evolution of vertebrates from early deuterostomes 
(Meyer and Schartl, 1999). Some of these duplications turn into pseudogenes or DNA that is not 
transcribed for usage, but many become genes that are responsible for a variety of new 
functions. Zebrafish are advantageous when it comes to studying developmental biology 
because of their small size, quick generation, and their ability to produce numerous offspring. 
The adult zebrafish is often no larger than two inches in length and when fed properly, can 
breed weekly. Hundreds of embryos can be collected from one mating, which allows 
researchers to have many replicates for experiments.  
The transparency of the zebrafish embryo at critical developmental stages, as well as its 
development external to the mother, makes the zebrafish useful to study organogenesis (Figure 
1.1b). Zebrafish are used to study heart, vessel, blood, kidney, and muscle development as well 
as other aspects of developmental biology (Ackermann and Paw, 2003; Lin, 2012). In our work, 
we use zebrafish to study heart development. Development of the heart can be studied in 
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zebrafish because of the similarity of early morphological events between human and zebrafish 
heart development. Zebrafish embryos obtain oxygen through diffusion for the first five to 
seven days post fertilization (Kopp et al., 2010; Hoage et al., 2012). This characteristic allows for 
the study of mutant genes that affect the heart structure and function. Our study involves using 
these embryos before they are dependent on the heart for oxygen. Since young embryos will 
not die due to lack of oxygen carried via the blood stream, blood flow can be altered to observe 




Figure 1.1 – Zebrafish are used as a model organism. A – Wildtype adult zebrafish. Male zebrafish is pictured on top 
while female zebrafish is picture on bottom. http://www.livescience.com/25180-zebrafish-change-color-for-








Morphogenesis of the heart is an essential process for life in complex animals. Many 
pathways and genes are involved in this process which can allow for mishaps to occur. These 
mishaps can cause congenital heart defects (CHD), which are estimated to be present in 4 to 10 
per 1000 live births in humans (Figure 1.2) (Pierpont et al., 2007; Fahed et al., 2013). 
Researchers are identifying genes that are responsible for these defects as well as the 
epigenetics or environmental conditions that affect the function or expression of those genes. 




Figure 1.2- Locations of heart malformations that are usually identified in infancy, and estimated prevalence based 
on the CONCOR database. Numbers indicate the birth prevalence per million live births. CONCOR database is a 
national registry and DNA-bank of patients with congenital heart disease in the Netherlands (Van der Velde et al., 
2005). AS – aortic stenosis; ASD – atrial septal defect; AVSD – atrioventricular septal defect; CoA – coarctation of the 
aorta; Ebstein – Ebstein anomaly; HLH – hypoplastic left heart; MA – mitral atresia; PDA – patent ductus arteriosus; 
PS – pulmonary stenosis; PTA – persistent truncus arteriosus; TA – tricuspid atresia; TGA – transposition of the great 




Heart development starts very early in zebrafish development (Figure 1.3) (Bakkers, 
2011). At just 5 hours post fertilization (hpf), cardiac progenitors (identified by fate-mapping 
experiments) are present in the lateral marginal zones of the cleavage stage embryo (Tu and 
Chi, 2012). Following gastrulation, cells from the anterior lateral plate mesoderm migrate 
towards the midline and differentiate into ventricular and atrial cardiomyocytes (Tu and Chi, 
2012). Heart tube formation occurs around 24 hours post fertilization, at which point the 
embryo is still translucent and visualization of ongoing development is possible (Yelon, 2001). 
At 24 hours post fertilization the heart tube starts to elongate, and turn so that the ventricle 
becomes anterior and the atrium becomes posterior (Tu and Chi, 2012). This movement 
precedes the looping of the heart, ballooning of the chambers, and formation of the 
atrioventricular canal; looping ends around 48 hours post fertilization (Tu and Chi, 2012). After 
48 hpf, the heart consists of a sinus venosus (the inflow tract that collects blood from cardinal 
veins and delivers it to the atrium), one atrium (a muscled cavity that receives deoxygenated 
blood and delivers it to the ventricle), one ventricle (receives blood from the atrium and 
delivers it to the body via the aorta). During this time, the bulbus arteriosus (a pear shaped 
ha e  th ough hi h lood lea es the hea t  develops (Grimes et al., 2006). While the 
heart is forming, cells are rearranging and beginning to communicate in a way that enables 





Figure 1.3 - Stages of cardiac development. At 5 h post fertilization, cardiac progenitor cells are located bilaterally 
in the lateral marginal zone. Atrial progenitor cells (pink) are located more ventrally than the ventricle progenitor 
cells (light blue). During mid- and late-somite stages, the myocardial tissue expands by continuous cardiogenic 
differentiation into more lateral regions of the anterior lateral plate mesoderm (ALPM) by the cardiogenic 
differentiation of future atrial myocytes (orange; venous differentiation). Cardiac morphogenesis transforms the 
cardiac disc into a cardiac tube. The endocardium forms the inner lining of the myocardial tube. At 28 hpf, the linear 
heart tube has formed, with the venous pole located at the anterior left and the arterial pole fixed at the mid-
line. Cardiogenic differentiation continues at the arterial pole, and as a result new cardiomyocytes are added to this 
region (purple gradient). At 36 hpf, cardiac looping has started, with a displacement of the ventricle towards the 
mid-line, and the constriction at the position of the AV canal is first visible. The heart tube continuous to loop and 
forms an S-shaped loop. Ellipsoid extra-cardiac pro-epicardial cells (brown) are located near the AV canal (yellow), 
from where they start to cover the myocardium with an epicardial layer. The pacemaker is present in the inner 
curvature of the atrium near the venous pole (dark green) (Bakkers, 2011). 
 
Cardiac conduction is the process responsible for providing a coordinated beat in the 
heart, while contraction is defined as muscle constriction in response to the conduction signals. 
These processes underlie the mechanics of a heartbeat, which provides the force that propels 
blood flow. Since zebrafish are small, embryos obtain sufficient oxygenation by diffusion to 
survive without a beating heart for the first 5 days of life (Hoage et al., 2012). However, normal 
development of the heart itself nevertheless requires a heartbeat and intracardiac flow (Banjo 
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et al., 2013). When flow is perturbed, morphological defects such as an abnormal chamber 
shape and size, a reduction in looping, and defective valve formation occur (Hove et al., 2003).  
Heart beat and contraction influence the formation of the trabeculae (myocardial sheets), the 
atrioventricular valve, as well as other cardiac structures (Staudt and Stainier, 2012). The 
heartbeat relies on a coordinated conduction system that is maintained by a specialized 
network of cardiomyocytes and is seen in both larval and adult zebrafish (Staudt and Stainier, 
2012). This conduction pattern allows contraction to move the blood cells efficiently through 
the heart, resulting in sustained blood flow (Staudt and Stainier, 2012). Although laminar flow 
begins as early as 20 hpf, conduction patterns begin to arise around 24-26 hpf, which indicates 
the presence of pacemaker tissue (Glickman and Yelon, 2002; Staudt and Stainier, 2012; Lee et 
al., 2013; Parker et al., 2014). Contractile patterns rely on the correct morphology of the heart 
as well as the correct formation of contractile sarcomeres (Staudt and Stainier, 2012). Along 
with flow, heart beat and contraction are necessary for the early development of the heart 
(Staudt and Stainier, 2012). Biomechanical factors related to contraction, stretch, or blood flow 
can affect both cell size and myofibril content (Lin et al., 2012).  
Biomechanical factors are considered epigenetic factors because they modify gene 
expression without altering the genetic code. To determine whether these epigenetic factors 
could impact chamber morphology, weak atrium (wea) mutants were investigated (Lin et al., 
2012). wea mutants have a loss of function mutation in the atrial myosin heavy chain (amhc) 
gene, which is expressed in the atrium but not the ventricle (Berdougo et al., 2003). Cell 
boundaries and Z-bands were labeled to observe cell size and myofibril content (Lin et al., 
2012). At 28 hpf, cell size and myofibril content in wea mutants was similar to wild type 
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embryos, but at 38-50 hpf, cell size and myofibril content differed (Lin et al., 2012). Z-bands 
were not only fewer per cell in wea mutants, but also shorter (Lin et al., 2012). The changes 
observed in this experiment suggest that hemodynamic forces influence cell size and myofibril 
content in the developing ventricle. This data led the researchers to assess the hypertrophic 
behavior of individual cardiomyocytes to see if diminished blood flow impacted them (Lin et al., 
2012). To do this, an atrial myosin heavy chain knockdown was used to recreate the wea 
mutant phenotype in embryos that had Z-bands labeled via α-actinin3b:egfp (Lin et al., 2012). 
Even though amhc is only expressed in the atrium and the ventricles do contract normally with 
normal sarcomeres, the ventricular chamber in wea mutants is smaller than wildtype (Auman 
et al., 2007). In wildtype embryos, cardiomyocytes hypertrophy (excessive development of a 
tissue) as part of the mechanism of chamber emergence (Lin et al., 2012). Few cardiomyocytes 
showed hypertrophic growth in the wea depleted embryos and the growth that did occur was 
less marked than that of wild type embryos (Lin et al., 2012). These results suggest that blood 
flow through the ventricle influences cardiomyocyte hypertrophy and myofibril content (Lin et 
al., 2012). 
To demonstrate that the detection of flow is important for cardiac development, 
ventricular cells in mutant and wildtype fish were observed. In wea mutants, elongation and 
surface area growth is reduced in ventricular cells (Auman et al., 2007). Ventricular cell growth 
is a cell nonautonomous trait based on the observation that the wea ventricular cells grow 
normally when transplanted into wild-type hearts (Auman et al., 2007). This experiment 
supports the idea that detecting flow is a necessary feature of ventricular cells and is important 
for cardiac development.   
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In a study investigating endocardial cushion development, Bartman and colleagues 
showed that myocardial contractility, a biomechanical force, alone may be responsible for 
inconsistencies in cardiac morphology in wildtype embryos (Bartman et al., 2004). Endocardial 
cushions (ECs) are tissue swellings made of endocardial cells that develop along the anterior-
posterior axis of the heart tube and are formed during late cardiac organogenesis (Bartman et 
al., 2004). ECs help in valve formation and in the case of four-chambered hearts, septae 
(Bartman et al., 2004). Epithelial-mesenchymal transformation (EMT), a process that allows for 
an epithelial cell to assume mesenchymal cell phenotypes, is a required sub-step for EC 
development and the events preceding and following EMT are being investigated (Kalluri and 
Weinberg, 2009). To determine if blood flow or myocardial function impacted EC development, 
various concentrations of 2,3-butanedione monoxime (2,3-BDM), a dose-dependent 
myofibrillar ATPase blocker, were applied along with tricaine (a fish anesthetic) to inhibit 
myocardial function (Bartman et al., 2004). At high concentrations of 2,3-BDM when blood flow 
is abolished, 58% of embryos formed an endocardial ring. Embryos that exhibited blood flow (at 
low concentrations of 2,3-BDM) still formed ECs, and conversely, when myocardial function was 
decreased (observed in embryos that lack a heartbeat), the number of embryos with 
functioning ECs decreased (Bartman et al., 2004). This result shows that poor myocardial 
function, not blood flow, is primarily responsible for the loss of endocardial cushion formation 
in mutant embryos. While blood flow is not shown to be important here, this is only a limited 
experiment looking at one type of morphology. This result also shows that myocardial function 
is an important factor in cardiac morphology, which will also be discussed here in this study. 
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An area of current interest within the field of embryonic heart development concerns 
how blood flow factors like shear stress and reverse flow impact gene expression and 
development of the heart. These factors involve analyzing different mechanisms of 
mechanotransduction which is a cellular process that converts mechanical stimuli into 
electrical, biochemical, and genetic responses (Sidi and Rosa, 2004; Miyasaka et al., 2011). 
Physical micro-environmental parameters that must be taken into consideration when 
discussing mechanotransduction include stresses and strains (Bukoreshtliev et al., 2013). 
Stresses are defined as the ratios of an applied force to the area upon which it is acting, which 
can then cause relative elongations or displacements of a material, or strains (Bukoreshtliev et 
al., 2013).   
In zebrafish, mechanical strains diffuse throughout the tissue and are largely caused by 
physical forces (Banjo et al., 2013). By observing the function of microRNA-21 (miR-21), which 
senses blood flow and uses these diffuse forces to regulate valve formation, Banjo and 
colleagues found that these forces a t as a ph si al o phoge  si e the  a  e dist i uted 
throughout the area, causing anisotropic distribution of strains (Banjo et al., 2013). Expression 
of miR-21 is dependent on hemodynamics as was shown in silent heart (sih) morphants (Banjo 
et al., 2013). When the heart beat is stopped in these morphants, expression of miR-21 is not 
present at its normal expression locations in the constricted parts of the endocardium (Banjo et 
al., 2013). These results present the idea that blood flow stimulates miR-21 expression, showing 
through correlation that miR-21 is a component of a mechanotransduction pathway (Banjo et 
al., 2013).  
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One blood flow factor being investigated in this study is reverse flow fraction (RFF). RFF 
is defined as the flow of fluid opposite to the normal direction or path of blood circulation, or 
specifically the flow from the ventricle back to the atrium after contraction. Our group and 
others have developed high speed video methodology to record the blood cells as they move 
through the atrioventricular junction, which permits extraction of RFF and other parameters. 
Valves in the heart prevent reverse flow, but before valves are formed there is substantial 
regurgitation. Reverse flow may serve as a critical signal to endothelial cells based on the 
observation that malformed valves develop if flow is severely perturbed (Vermot et al., 2009). 
Reverse flow in zebrafish is highest in the AV canal during the second and third days of 
development, which are the times that precede valve formation (Vermot et al., 2009). A low 
percentage reverse flow fraction (RFF) indicates that little reverse flow is present, which may 
cause developmental defects like malformed heart valves (Vermot et al., 2009). 
Along with reverse flow, shear stress is another flow defining factor. Shear stress is an 
epigenetic force that is classified as the frictional force caused by the pressure exerted upon the 
endocardium by blood cells (Gijsen et al., 2013). The total mechanical load that is detected by 
the endocardium is represented partially by shear stress (Gijsen et al., 2013). When shear stress 
is greatly increased or changed in some manner, the embryonic heart experiences detrimental 
effects. The endothelium is particularly sensitive to shear stress and appears to be a primary 
sensor of shear stress (Gijsen et al., 2013). In addition to RFF, the presence or magnitude of  
fluid shear stress appears to prompt biochemical pathways within endothelial cells during 
development that are required for chamber and valve morphogenesis (Santhanakrishnan and 
Miller, 2011). In developing chicks, left atrial ligation shapes how myofibers in the embryonic 
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heart form during cardiac morphogenesis and therefore impacts chamber dimensions 
specifically in the ventricle (Tobita et al., 2005). In chicks with venous obstruction, 
malformations in the ventricular septum and the pharyngeal arch artery also occur (Hogers et 
al., 1999). These changes are outcomes of a change in shear stress in the chick (Hove et al., 
2003).  
Shear stress is also important in the development of bone (Piekarski and Munro, 1977). 
A recent study in rats has shown that osteocytes are subject to a maximum shear stress 
stimulus but can also sense low-fluid shear stress (Verbruggen et al., 2014). Rosa and colleagues 
suggest that shear stress is the stimuli most recognized by osteocytes in comparison with 
mechanical strain (Rosa et al., 2015). This shows that shear stress is an important factor not 
only in cardiac morphogenesis, but also bone morphogenesis.  
In zebrafish, the bead obstruction experiments by Hove et al (2003) suggest that hearts 
developing in conditions of impaired cardiac flow demonstrate three major phenotypes: an 
absent or malformed bulbus, abnormal cardiac looping, and abnormal development of the 
inflow and outflow tracts (Hove et al., 2003). Blood flow is also critical in the developing valves 
themselves for cell shape changes and leaflet invagination in zebrafish (Vermot et al., 2009). 
Stopping blood flow in zebrafish embryos by bead implantation results in erythrocyte 
accumulation within the heart chambers, leading to defects to the embryonic heart (Hove et al., 
2003). These defects result in a dramatic reduction of shear forces against the heart and 
phenotypes mentioned above (Hove et al., 2003). 
 Genetic studies indicate that epidermal growth factor receptor tyrosine kinase (EGFR) 
has cardiovascular function in zebrafish (Goishi et al., 2003). Inhibiting EGFR  in zebrafish by 
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EGFR kinase inhibitors and EGFR morpholinos results in impeded outflow into the aorta, 
impeded circulation in the axial and intersegmental vessels, and dilated pericardial sacs and 
heart chambers (Goishi et al., 2003). These phenotypes suggest that EGFR has a function in 
cardiovascular development, so manipulating EGFR can help determine whether shear forces 
have an impact on the formulation of the heart (Goishi et al., 2003). 
 Hove and colleagues performed studies to determine if shear stress has an impact on 
the development of the embryonic heart and by what mechanism, which involved looking at 
the levels of gene expression in cardiac endothelial cells (Hove et al., 2003; Auman et al., 2007). 
Flow-induced forces direct changes in cardiac endothelial cell gene expression (Davies, 1995). In 
vivo shear stress calculations predict wall shear stresses range from 2.5 dyn cm-2 to 76 dyn cm-2 
in 36 hpf to 4.5 days post fertilization (dpf) embryos respectively (Hove et al., 2003). The 
stresses increase as the embryo grows and forms more blood cells. Shear stresses that are less 
than 1 dyn cm-2 result in up- or down-regulation of gene expression in cardiac endothelial cells 
in vitro (Hove et al., 2003). Both the 36 hpf and the 4.5 dpf embryos demonstrate shear forces 
that are above the low threshold of detection by cardiac endothelial cells (Hove et al., 2003). 
This data suggests that shear forces play an important role in the regulation of cardiac 
morphogenesis during embryogenesis (Hove et al., 2003).  
In chick, the changes of shear stress and aortic arch (AA) diameter are closely correlated 
(Kowalski et al., 2013). Throughout different stages of AA development, specifically stages 18-
24, variable levels of shear stress were observed (Kowalski et al., 2013). At stages 18 and 24, 
shear stress levels were at 1-3 Pascals (Pa), while at stage 21 shear stress levels were in the 3-7 
Pa range (Kowalski et al., 2013). The increased shear stress at the intermediate stages lead 
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researchers to speculate that increases in shear stress triggered changes in genetic signaling 
pathways that correlated with significant changes in AA growth (Kowalski et al., 2013). The 
decrease at stage 24 back to the original level (3-7 Pa) suggests mechanical restoration, which 
a o di g to the autho  is a theo  i t odu ed fo  io e ha i all - egulated g o th  
(Kowalski et al., 2013). Ta e s hi k e o i  studies des i e ho  tissues espo d to 
homeostatic or optimal loading conditions (Taber and Eggers, 1996; Taber et al., 2001). 
Ko alski s omputational fluid dynamics simulations determined that the diameters of AAs 
statistically correlate with shear stress and vessel diameter (Kowalski et al., 2013). Combining 
these thoughts provides a hypothesis to investigate the relationship between hemodynamics 
with development of cardiac vasculature to lead to insight into forms of CHD.   
As the heart develops, communication needs to occur among cells, proteins, and 
extracellular components to relay the effects of mechanotransduction. These communications 
are called mechanotransduction. Mechanotransduction research is often focused on sensory 
cells that are near areas of dynamic change (Jaalouk and Lammerding, 2009). These cells range 
from hair cells in the inner ear, endothelial cells in the heart and vasculature, and cells lining the 
gut. Tissues must be able to respond to changes in their environment and these sensory cells 
can initiate the communication. The sensory cells may contain cilia which will be responsible for 
relaying messages to the intercellular network. In the developing heart, sensory cells have not 
yet been identified and mechanotransduction is not yet fully understood (Boselli et al., 2015). 
Current interest lies in figuring out what pathways are involved in relaying information from the 
sensory cells to downstream targets. 
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One way to observe mechanotransduction and the messages sent from one cell to 
another is to learn how the cells are sensing flow via molecular mechanisms. The zinc finger 
transcription factor Krüppel-like factor 2 (Klf2) is important in mechanisms linking shear stress 
signals to changes in gene expression in mammals (Dekker et al., 2005). This zinc-finger 
transcription factor also regulates many vasoactive endothelial genes (Lee et al., 2006). Studies 
in mammals have shown KLFs to be important in the control of hematopoietic and other types 
of cell differentiation (Oates et al., 2001). Mammalian KLFs share the same ancestral gene, 
Krüppel as in Drosophila (Nagai et al., 2009). In Drosophila, Krüppel is involved in early 
development and segmentation of the thorax and abdomen (Nagai et al.). Mammalian KLFs are 
involved in embryogenesis and fetal development (Nagai et al.). In zebrafish, klf2a is 
orthologous to the KLF2 that is expressed in mouse and chick (Oates et al., 2001). Mouse 
embryos with a deficiency of KLF2 die after E11.5 (when the atria are separating from the 
ventricles) from heart failure that is caused by a loss of peripheral vascular resistance resulting 
in defective endothelial cell function (Lee et al., 2006). Mouse KLF2 is expressed in embryonic 
endocardial cells and is up-regulated by a loss of endocardial signaling in the cerebral cavernous 
malformation (CCM) pathway (Zhou et al., 2015). The CCM pathway is responsible for 
preventing postnatal vascular malformations and is required in endocardial cells (Zhou et al., 
2015). CCM pathway genes were deleted in mice which resulted in embryonic heart failure and 
reduced myocardial growth (Zhou et al., 2015). Zhou and colleagues demonstrated that KLF2 
and KLF4 are regulated by MEKK3 (a mitogen-activated protein kinase that binds CCM2 in 
endothelial cells) in response to fluid flow (Zhou et al., 2015).  
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In chick, a venous clip leads to a disruption in blood flow which results in an increase in 
KLF2 mRNA levels in endothelial/endocardial cells (Groenendijk et al., 2005). The change in 
expression levels of KLF2 is caused by an increase in cardiac shear stress (Groenendijk et al., 
2005). A study by Groenendijk and colleagues shows that the most pronounced changes in 
shear stress occurred in the upstream slope of the outflow tract (Groenendijk et al., 2005). This 
location is susceptible to a multitude of cardiac malformations such as ventricular septal 
defects, semilunar valve abnormalities, and outflow tract malformations (Groenendijk et al., 
2005). Since KLF2 expression is related to shear stress changes, Groenendijk and colleagues 
proposed that KLF2 mis-regulation might contribute to development of some or all of these 
malformations. Moreover, KLF2 regulates the expression of other shear stress-related genes, 
endothelin-1 (ET-1) and endothelial nitric oxide synthase (NOS-3) (Groenendijk et al., 2005). 
These two genes are downstream of KLF2 and are responsible for pathways that are involved in 
cardiac processes (Figure 1.4) (Groenendijk et al., 2005).  
Studies in zebrafish have also supported a critical role for klf2a as a flow-responsive 
gene. As previously mentioned, klf2a is a transcription factor that is responsive to shear stress 
and is expressed in endothelial cells (Groenendijk et al., 2005; Lee et al., 2006; Wang et al., 
2011). Zebrafish klf2a is a flow-response gene and its expression is highest in the 
atrioventricular junction (AVJ) in the developing heart (Vermot et al., 2009). Genetic 
knockdown studies indicate that klf2a is essential for endocardial morphogenesis including 
both valve formation and endocardial cell surface area which contribute to normal heart 




Figure 1.4 - Scheme, showing the presumed influences of altered gene expression by changes in shear stress on 
biological processes leading to congenital heart malformations. a, described in endothelial cells. b, described in 
s ooth us le ells a d fi o lasts. ?  i di ates u lea  hethe  ETB defi ie  esults i  a dio as ula  
malformations; +, increase in NO or the processes; interrupted arrow, knockout studies showing cardiovascular 
malformations. (Groenendijk et al., 2005) 
 
 
In the zebrafish sih mutant, embryos do not have a contractile heart (Parmar et al., 
2006). In sih homozygous embryos and other mutants with reduced, increased reversed, or 
absent blood flow, klf2a expression is down-regulated or absent and hearts exhibit increased 
valve dysgenesis. These data are consistent with the hypothesis that klf2a acts downstream of 
biomechanical factors related to blood flow, and is transcriptionally responsive to these forces 
(Parmar et al., 2006; Vermot et al., 2009). When klf2a is knocked down via morpholino, 
embryos showed the expected normal cardiac contractility and normal blood flow at 48 hpf 
(Dietrich et al., 2014), but the atrioventricular valves function was reduced by 96 hpf in 52% of 
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embryos (Vermot et al., 2009). These morphants, however, still showed similar heart rate and 
blood flow patterns compared to control embryos (Vermot et al., 2009).  
Dietrich and colleagues found that embryos with overexpression of klf2a via endothelial 
promoter constructs showed a significant decrease in endocardial cell sizes, suggesting that 
klf2a mediates endocardial cell size in response to blood flow (Dietrich et al., 2014). 
Collectively, these data suggest that klf2a serves as a critical molecular link mediating valve 
formation as a response to normal biomechanical input derived from blood flow. 
There are a total of 22 Krüppel-like factors in zebrafish (ZFIN.org). Other zebrafish 
Krüppel-like factor genes that are paralogous to klf2a include klf2b and klf4 (Oates et al., 2001). 
Klf2a is the smallest protein of the three with 347 amino acids while Klf2b and Klf4 have 363 
and 409 amino acids respectively. The Klf2b and Klf4 proteins are similar to mammalian KLF2 
mostly in the C-terminal region where the zinc finger domains are located (Figure 1.6A) (Oates 
et al., 2001). The C-terminus consists of three tandem zinc finger domains which are highly 
conserved throughout the KLF family members (Figure 1.5A) (Oates et al., 2001). In contrast, 
regions outside of the finger domains are strongly diverged throughout the KLF family (Oates et 
al., 2001). Zebrafish Klf2a, Klf2b, Klf4 and mouse KLF2 and KLF4 share 5 blocks of conserved 
sequence within the N-termini  (Figure 1.5C) (Oates et al., 2001). These blocks are separated by 
divergent regions and contain potentially functional domains (Oates et al., 2001). Thus, these 
zebrafish KLF genes encode proteins with significant similarity to the mammalian protein.  
Although transcriptional profiling studies do indicate cardiac expression for klf2b, little is 
known about the function of this gene other than its role as a transcription factor (Bastian et 
al., 2008). One study showed, by in situ hybridization, that at 48 hpf klf2b expression is present 
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in the central mesenchyme of the pectoral fin bud and in the adjacent cleithrum of the shoulder 
girdle (Yokoi et al., 2009). Based on in situ hybridization, no expression has been reported later 
than 48 hpf, although expression has been shown in ectoderm, neural crest, and periderm in 
early embryonic stages from 50% epiboly to 20-25 somites (Thisse, 2001). 
 
 
Figure 1.5 - Evolutionary relationships among Krüppel-like factor (KLF) genes. (A) Amino acid alignment of the C-
terminal zinc finger domains of zebrafish KLF proteins with selected vertebrate KLF proteins and Drosophila 
KRUPPEL. Amino acid identity is marked with black and similarity with gray highlighting. Asterisks mark the invariant 
zinc-chelating residues, and the arrows indicate those residues that contact the DNA. (B) Phylogenetic tree of the 
evolutionary relation of zebrafish KLF genes to their close vertebrate relatives and Drosophila Krüppel, based on the 
sequences of the zinc finger domains of the respective proteins. Numbers give the bootstrap support for given nodes 
in the phylogram. (C) Amino acid alignment, excluding the zinc finger domain, of the N-termini of zebrafish Klf2a, 
Klf2b, and Klf4 proteins with their closest vertebrate relatives Klf2 (Lklf) and Klf4 (Gklf). Regions of high similarity are 
numbered and indicated with brackets; see text for details (Oates et al., 2001).  
 
 
Expression of klf4 was detected in the hatching gland, lateral line ganglia, neuromasts, 
and blood (Thisse, 2004). Depletion of klf4 in zebrafish via morpholino led to anemia, 
pericardial edema, hatching defects, and a defect in hemoglobinisation of the red blood cells 
(Gardiner et al., 2007; Bastian et al., 2008). In mice and human endothelial cells, klf4 regulates 
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endothelial inflammation (Hamik et al., 2007). klf4 also plays a role in dedifferentiation and 
reprogramming of somatic cells, and is under intense study as a mediator of induced 
pluripotency in the generation of iPS cells (Christen et al., 2010). In bungee mutant zebrafish, a 
missense mutation in the zebrafish protein kinase D2 (pkd2) gene caused valve formation to be 
perturbed by depleting endocardial Notch signaling in cardiac cushions (Just et al., 2011). In 
these mutant hearts, klf2a and klf4 RNA levels are severely reduced at the AV boundary and the 
cardiac outflow tract (Just et al., 2011).The bng mutants do not form AV valves (Just et al., 
2011). klf2a regulates Notch expression and is necessary for valve formation (Parker et al., 
2014). The role of klf4 in regulating valve formation has not yet been determined, but its 
cardiac expression and altered phenotype in bng mutants suggest a potential contribution to 
valve formation. 
Since klf2a is a known flow response gene, to understand its mechanism, Vermot and 
olleagues  lood flo  as alte ed  alte i g blood viscosity and modulating pacemaker 
activity in zebrafish (Vermot et al., 2009). These researchers manipulated a gene that encodes 
hematopoietic transcription factor gata2. Along with gata1, gata2 is a hematopoietic 
transcription factor that is expressed during early embryogenesis (Stainier et al., 1995). 
Zebrafish embryos that are homozygous for a loss-of-function mutation in gata2 show a 
significant loss in hematopoietic stem cells, but have no malformations in vasculature (Stainier 
et al., 1995). This result makes knocking down gata2 ideal for identifying phenotypes associated 
with change in shear stress and reverse flow since no other consequences in the vascular 
system or overall body plan are observed. The data shown in Figure 1.8 represents the 
phenotypes obtained when gata1 or gata2 were knocked down via morpholino (Vermot et al., 
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2009). Two main outcomes associated with this gene knockdown include lowered blood 
viscosity and altered hematocrit levels  (Figure 1.8) (Vermot et al., 2009). Normally, wild type 
embryos exhibit a reverse flow fraction of 35% (Vermot et al., 2009). When morpholinos were 
injected (separately), gata1 morphant embryos demonstrated increased RFF (45% of the 
cardiac cycle), hematocrit levels were reduced 90%, but embryos still developed normal valves 
at 96 hpf. In contrast, gata2 morphant embryos demonstrated decreased RFF (17%), 
hematocrit levels were reduced by 70%, and embryos exhibited severe valve defects (Vermot et 
al., 2009). This great reduction in reverse flow leads to 36% of embryos with normal valve 
development compared to 100% in the control and 78% in the gata1 knockdown (Vermot et al., 
2009). These data indicate that surprisingly, RFF rather than hematocrit levels per se, was the 
phenotype associated with valve dysgenesis. To further determine whether valve dysgenesis 
was related to a decrease in RFF, the effects of double gata knockdown were explored. When 
gata1 and gata2 were injected simultaneously, RFF was close to wildtype levels at 50%, 
hematocrit was severely reduced, and valve formation was normal (Vermot et al., 2009).  
Collectively, these data pinpoint appropriate amounts of RFF as a necessary factor for normal 
valve development (Vermot et al., 2009). 
Reverse blood flow has been examined in other species as well. In response to hypoxia 
at 5% and 10% oxygen levels, quail embryos show an increase in reverse flow in about half of 
the tested specimens (Gu et al., 2012). Gu and colleagues did not report whether chick embryos 
developed any developmental defects associated with acute hypoxia. However, heart rate was 
noticeably slower, with some embryos skipping beats, eventually leading to death (Gu et al., 
2012). This study was done in quail embryos before valve development, around the stage of 
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cardiac looping (Martinsen, 2005; Gu et al., 2012). In quail, Gu and his colleagues demonstrated 
that there is little reverse flow preceding the upstroke of each heartbeat, which shows that 
hypoxia is another way to induce rapid hemodynamic changes in the developing embryo (Gu et 




Figure 1.6 – Clustal Omega alignment of Klf2a, Klf2b, and Klf4 protein sequences. A – Top sequence – Klf4. Middle 
– Klf2b. Bottom – Klf2a. B – Percent identity.  
 
 







Figure 1.8 – Overview of outcomes by manipulating oscillatory flow by decreasing circulating blood cells. Outline 
showing results of morpholino injections versus control. Gene expression color code (in order): bmp4, notch1b, edn1, 
nrg1, klf2a (Vermot et al., 2009). 
 
A second method for manipulating flow dynamics in the embryonic heart arose from 
our study of filamin C (flnc),a sarcomeric protein expressed exclusively in skeletal and cardiac 
muscle (Valdes-Mas et al., 2014). Human filamin C mutations result in a filamin-related 
myofibrillar myopathy (Ruparelia et al., 2012). Myofibrillar myopathies (MFM) are a result of 
muscle dissolutions or muscle break down, starting at the Z-disc. In skeletal muscle of MFM 
patients, aggregation of sarcomeric proteins and fibril fibrosis (tissue thickening) is exhibited 
(Ruparelia et al., 2012; Valdes-Mas et al., 2014). Clinical studies show that patients with flnc 
mutations have a higher frequency of cardiac death (Valdes-Mas et al., 2014). Although its 
precise role is not known, flnc is implicated in familial human hypertrophic cardiomyopathy 
(Valdes-Mas et al., 2014).  
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Ruparelia and colleagues described a filamin Cb (flncb) zebrafish mutant called stretched 
out (sot) (Ruparelia et al., 2012). sot mutants demonstrated defects in muscle and motor 
neuron development, specifically in the integrity of slow muscle fibers (Figure 1.9a) (Birely et 
al., 2005). The zebrafish genome also encodes a filamin Cb paralog, filamin Ca. When both 
genes are knocked down via morpholino, the somites show failure to develop or maintain 
almost all slow muscle fibers (Figure 1.9a) (Ruparelia et al., 2012). Unlike sot (flncb) mutants, 
the double flnc knockout also affects fast muscle fibers (Ruparelia et al., 2012). Although the 
flnc depletion phenotypes for skeletal muscle were reported, (Ruparelia et al., 2012), cardiac 
phenotypes are not yet described. Skeletal muscle and cardiac muscle are similar in that both 
are striated, exhibit strong contractions, and contain sarcomeres – the contractile unit of 
muscle. In skeletal muscle, filamin C is a key component of muscle integrity and is localized at 
the junction of the Z-disc and the sarcolemma, known as the costamere (Ruparelia et al., 2012). 
Filamin C plays an important role in the maintenance of muscle structure especially during the 
onset of contraction (Thompson et al., 2000; Ruparelia et al., 2012). The main role of cardiac 
muscle is contraction which is responsible for moving blood throughout the body. Failure to 
maintain muscle structure in the heart could lead to devastating effects for the organism. A 
study examining hypertrophic cardiomyopathy (HCM) identified filamin C has a potential gene 
implicated in this human disease (Valdes-Mas et al., 2014). Valdes-Mas and colleagues describe 
multiple flnc variants within families who have a history of HCM and show that these variants 




Figure 1.9a – sot, filamin Cb MO, filamin Ca MO, and filamin Ca+Cb MO phenotypes (B) Slow myosin heavy chain 
antibody labeling of uninjected control embryos at the 26-somite stage showing normal striated muscle fibers. (C) 
Sporadic failure of slow muscle fibers and the aggregation of myosin at the somatic boundaries is evident in sot 
mutants and flnca morphants (flnca MO). (E) Loss of both filamin C proteins results in failure of all slow muscle fibers 
(Ruparelia et al., 2012). 
 
 
Figure 1.9b – sot, filamin Cb MO, filamin Ca MO, and filamin Ca+Cb MO phenotypes (C and D) F59 antibody labeling 
of slow muscle in uninjected (C) and flncb morpholino-injected embryos (D) showing reproduction of the sot 
phenotype (Ruparelia et al., 2012). 
  
This study will examine how biomechanical factors such as flow and cardiac contraction 
impact gene expression of flow response genes or the formation of chambers and valves. Using 
tools such as morpholinos, high speed imaging, and qPCR, we investigated hypotheses of how 
shear stress and reverse flow impact the developing heart. The anticipated outcome of the 
study is to identify biomechanical factors that may play a role in atherosclerosis, 





 In Aim 1, we observed the expression levels of klf2a, klf2b, and klf4 via RT-PCR in both 
whole embryos and embryonic hearts, and in situ hybridization. In Aim 2, we examined the 
influence that shear stress and reverse flow exerts on the expression of klfs in the developing 
zebrafish heart. We manipulated the expression of two genes to alter shear stress and reverse 
flow. 
First, to extend the study of Vermot and colleagues on the role of reverse flow on klf2a 
expression, we knocked down gata2 and examine the expression levels of klf2a, klf2b, and klf4 
(using klf2a as an expected positive control) in zebrafish hearts at 56 hpf. At 48 hpf, high speed 
imaging will accurately measure reverse blood flow fractions as well as shear rate (frictional 
force within the heart caused by blood flow) in response to the lowered blood viscosity. This 
data will then be analyzed together to see how changes in blood viscosity affect the expression 
of klf2b and klf4, compared with klf2a.  
Second, using the recent findings from our lab regarding flncb, we will use morpholinos 
to knock down this gene to investigate whether there are changes in shear stress and reverse 
flow in response to a change in muscle structure and perhaps contractility. Videos of these 
morphants were observed in our lab and a visible increase in reverse flow was noted, hinting 
that flow patterns in the embryonic heart are abnormal. After videos are analyzed to provide 
quantitative information on the hemodynamics in the 48 hpf heart, we will then dissect 
embryonic hearts at 56 hpf to collect RNA. We will then explore expression levels of klf2a, 
klf2b, and klf4 in response to the knockdown of flncb.  
Together, this data will provide insight into the hemodynamics of the wildtype 
embryonic heart compared to hemodynamics in response to a change in blood viscosity or 
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heart contractility. This project will provide data that will show that hemodynamics is an 
important contributor to the morphology of the developing heart, which will provide insights 













































Congenital heart defects are birth defects estimated to arise every 50 per 1000 births 
(Pierpont et al., 2007). To investigate mechanisms that may cause congenital heart defects, 
model organisms such as the mouse, chick, and zebrafish are very useful. The mouse is a model 
organism for developmental biology because it is a mammal. However, offspring develop inside 
of the mother so they are not ideal for observing early development. The chick is a tool for 
developmental biology because chickens generate large eggs that develop outside of the 
mother while a downside is that offspring are generated in lower yields. Zebrafish are ideal 
because they are vertebrates, their heart develops similarly to human hearts, they have 
transparent embryos that develop outside of the mother, and they give clutches of embryos in 
the hundreds.  
 Hemodynamics is the study of blood flow. Reverse flow, blood pressure, and shear 
stress are examples of important variables in hemodynamics. In the present study, we focus on 
analyzing reverse flow and shear rate through the heart. Previously, Vermot and colleagues 
found that reverse flow and shear stress are important for valve development in zebrafish 
(Vermot et al., 2009). We can improve on this study by more accurately measuring reverse flow 
through the heart by using blood volume fractions rather than time fractions. Here, shear rate 
will be analyzed as a factor instead of shear stress because we argue that viscosity should not 




 In this study, we have analyzed reverse flow and shear rate in embryos depleted for 
gata2 and flncb using morpholino antisense oligonucleotides. The gata2 transcription factor is 
responsible for blood cell differentiation and when knocked down will result in lowered blood 
hematocrit, and therefore, lowered blood viscosity (Galloway et al., 2005). The flncb sarcomeric 
protein contributes to cardiac and skeletal muscle structure and when knocked down is 
predicted to result in a change in cardiac contractility (Ruparelia et al., 2012). Knocking down 
these two genes down by morpholino is an approach to manipulate reverse flow and shear rate 
in two different ways. In embryos knocked down for either gene, we observed survival, day four 
phenotypes, heart rate, cardiac output, reverse flow, shear rate, velocity of the blood, and gene 
expression. 
 In wildtype or knockdown embryo hearts, we analyzed klf2a, klf2b, and klf4 via qPCR for 
changes in expression levels that occur in response to lowered blood viscosity and changes in 
contractility. As described in Chapter 1, klf2a is a known flow response gene (Dekker et al., 
2002). We hypothesize that klf2b and klf4 are functionally similar to klf2a and are also flow 
response genes.  
In addition to analyzing potential flow response genes, we want to observe specific 
changes in cardiac function of the heart in response to lowered blood viscosity and changes in 
contractility. We hypothesize that lowered blood viscosity will result in reduced reverse flow 
and reduced shear rate through the AVJ. In hearts with altered contractility, we hypothesize 
that these embryos will exhibit increased reverse flow with increased shear rate.  
 Utilizing the data gained from this study, we will be able to understand how our target 
genes klf2a, klf2b, and klf4 change in expression level in response to changes in hemodynamics, 
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and how contractility and changes in blood viscosity alter expression levels and hemodynamics. 
This information will allow future researchers to connect what genes are important in 


























klf2a, klf2b, and klf4 are expressed at time points crucial to heart development in the embryo 
 To determine that our target genes are expressed in the embryo at times that are 
relevant to heart development, we performed RT-PCR using whole embryo RNA at a number of 
development stages. Heart progenitors are present as early as five hours post fertilization (hpf) 
(Bakkers, 2011). We started our developmental RT-PCR at two hpf in order to see if the genes 
were expressed before the cardiac progenitors are present. Figure 3.1 shows the results of the 
developmental RT-PCR using whole embryos. klf2a, klf2b, and klf4 are all expressed from two 
hpf to 72 hpf in whole embryos. Therefore, they are expressed at times crucial to heart 
development in the embryonic zebrafish.  
 
 
Figure 3.1 – klf2a, klf2b, and klf4 are expressed in early development. Whole embryo RT-PCR using gene-specific 











klf2a, klf2b, and klf4 are expressed specifically in the heart 
 To determine whether klf2a, klf2b, and klf4 are expressed specifically in the heart, we 
next tested for expression at stages including the heart tube (around 24 hpf) to the beginnings 
of valve formation (96 hpf) (Figure 3.2a). klf2a and klf4 are expressed in all stages examined, 
but klf2b does not have detectable expression until 48 hpf in the heart. 
 Since klf4 is an early marker of blood in the zebrafish, and expressed highly in the 
hematopoietic system (Oates et al., 2001; Gardiner et al., 2007), we needed to make sure that 
the expression in the heart samples was not solely due to blood still present in the heart at the 
time of dissection. To explore this idea, we utilized the gata2 morpholino. By knocking down 
gata2, we were able to obtain zebrafish embryos with no blood in their circulatory system and 
therefore dissect hearts free of blood. The PCR experiment with gata2 morpholino-injected 
embryos and non-injected wildtype embryos used cDNA that was extracted from embryos at 72 
hpf and 96 hpf, times in which blood is robustly circulating through the heart. We hypothesized 
that klf4 expression was not solely due to blood that was present in the heart, but due to 
actually being expressed in heart tissue. In the PCR results, klf4 is still detected in extracted 
hearts that contain no blood (Figure 3.2b). 
To determine the location of klf2a, klf2b, and klf4 expression in the heart, we performed 
in situ hybridization in wildtype embryos. cmlc2 (a cardiac myofibril assembly protein expressed 
throughout the heart) provided a positive control to show where the heart tissue was located 
at each stage (Figure 3.3). Hearts were outlined and placed on to their respective stages to 
show cardiac expression. klf2a was expressed in the heart at 36, 48, 56, 72, and 96 hpf (Figure 
3.3). Expression of klf2a was observed in the AVJ. klf2b expression was found at 36, 48, 56, 72, 
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and 96 hpf (Figure 3.3). klf2b expression was located in the ventricle and AVJ from 48 to 96 hpf. 
klf4 expression was detected at 36 and 48 hpf in the hatching gland (Figure 3.3). No detectable 
expression of each gene was found at 24 hpf (Figure 3.3). Cardiac expression for klf2a and klf2b 
is restricted to the AVJ and ventricle. This seems to be consistent throughout heart 





Figure 3.2 – klf2a, klf2b, and klf4 are expressed in the embryonic zebrafish heart. RT-PCR of isolated heart cDNA 
at stages encompassing early heart development. cDNA was transcribed using 2 micrograms of RNA. A – 
Expression patterns of klf2a, klf2b, and klf4 in embryonic stages during heart development. B – Comparing klf4 
expression patterns in embryos with no blood (gata2 –MO) versus non-injected control embryos at both 72 hpf 









Figure 3.3 – Cardiac expression locations of cmlc2, klf4, klf2a, and klf2b. In situ hybridization showing expression 
locations of klf2a, klf2b, and klf4. Gene expression for klf2a, klf2b, and klf4 is found in the heart at stages 
corresponding to heart development. cmlc2 is used as a positive control to show location and shape of heart at each 
stage. Hearts are outlined and transposed on respective stages.  
 
 
Decreased blood viscosity results in severe cardiac phenotypes and embryonic lethality 
 Once we determined expression patterns of klf2a, klf2b, and klf4, we investigated the 
effect of hemodynamics on heart development. Using depletion of gata2, we lowered blood 
viscosity in embryos. To observe how embryos with decreased blood viscosity are affected over 
a period of time, embryos were kept for ten days after injections and scored for survival (Figure 
3.4a). The gata2 morpholino results in lowered blood viscosity in the embryo. In addition, 
observations were made on the fourth day to investigate late-stage heart phenotypes 
compared to control embryos (Figure 3.4b). Embryos were scored for the following 
phenotypes: death, cardiac edema (edema around pericardial sac), stringy heart (heart that 
does not form ballooned chambers), low or no blood flow, reduced blood flow (visually reduced 
from wildtype blood flow, but flowing blood still present), wild-type blood flow, non-compact 
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heart (heart does not compact), no ventricle contraction (silent ventricle), weak or arrhythmic 
contractions, small chambers (chambers are visibly smaller than wildtype), other body edema 
(edema not related to pericardial sac, e.g. over the yolk sac), body axis defects (defects that 
affect patterning of body axis). Overall, embryos with lowered blood viscosity survived well, but 
the morphology of these embryos was altered, affecting the structure of the heart and 
impacting flow through the heart (Figure 3.4). These results show that a decrease in blood 
viscosity results in morphological cardiac defects with a modest effect on survival. 
 
Changes in contractility results in severe cardiac phenotypes and embryonic lethality 
 Our next approach to determining the effect of hemodynamics on cardiac 
morphogenesis is to deplete flncb. The knockdown of flncb results in a change in muscle 
structure due to flncb encoding a sarcomeric protein found in skeletal and cardiac muscle 
(Ruparelia et al., 2012). With this change in a sarcomeric protein comes a change in contractility 
which results in disrupted flow through the embryonic heart. The embryos with a change in 
contractility were tracked for survival rates and observed on day four of development for 
cardiac phenotypes (Figure 3.5). Non-injected wildtype embryos and 25N control morpholino-
injected embryos showed overtly normal development (with the exception of one embryo in 
25N control morpholino-injected group dying), but the flncb morpholino-injected embryos 
exhibited phenotypes such as: wildtype, death, cardiac edema, stringy heart, low or no blood 
flow, left/right asymmetry (where the heart loops with the ventricle on the left and atrium on 
the right), and silent ventricle (Figure 3.5b). 25N control morpholinos consist of 25 random base 
pairs in order to control for the morpholino injection. Compared to embryos with lowered 
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blood viscosity, the embryos with a change in cardiac contractility exhibited less effect on 
visible morphology and flow in the embryonic heart. These results show that a change in 
contractility and muscle structure of the heart overtly affected flow in at least 25% of embryos 
and produced modest morphological cardiac defects and death in about 20% of embryos. 
 
 
    
Figure 3.4 – Survival rate and four day phenotypes for gata2 morpholino-injected embryos. A – Survival rates of 
gata2 morpholino-injected embryos (n=156), gata2 mismatch morpholino-injected embryos (n=94), and non-
injected wildtype embryos (n=59). On day 10, 80.8% of gata2 morpholino-injected embryos were still alive. 78.7% 
of gata2 mismatch morpholino-injected embryos were still alive and 93.2% of non-injected wildtype embryos were 
alive. B – Phenotypes on day four are shown. All non-injected wildtype embryos exhibited normal development 
(n=37). 96.0% of the gata2 mismatch morpholino-injected embryos were wildtype with 4.2% dead (n=25). gata2 
morpholino-injected embryos exhibited a multitude of phenotypes: 58.9% were wildtype, 1.4% were dead, 38.3% 
had cardiac edema, 10.0% had a stringy heart, 27.7% had little to no blood flow, 7.8% had reduced blood flow, 3.6% 
had wildtype blood flow (not counting wildtype), 14.1% had non-compact heart, 5.0% had a silent ventricle, 2.1% 
had short or uneven contractions, 7.1% had small chambers, 4.3% had edema unrelated to the pericardial sac, and 






   
Figure 3.5 – Survival rate and four day phenotypes for flncb morpholino-injected embryos. A – Survival rates of 
flncb morpholino-injected embryos (n=111), 25N control morpholino-injected embryos (n=56), and non-injected 
wildtype embryos (n=17). On day 10, 62.3% of flncb morpholino-injected embryos were still alive, while 85.7% of 
25N control morpholino-injected embryos were still alive. 100% of non-injected wildtype embryos survived. B – 
Phenotypes of day four embryos. 100% of the non-injected wildtype embryos were wildtype (n=9). 97.9% of 25N 
control morpholino-injected embryos were wildtype while 2.1% were dead on day four (n=48). flncb morpholino-
injected embryos exhibited many phenotypes: 80.7% were wildtype, 1.8% were dead, 8.3% had cardiac edema, 9.2% 




Changes in hemodynamic patterns occur in the atrioventricular junction in embryos with 
decreased blood viscosity 
Reverse flow in the AVJ is defined as the portion of blood that is moving through in the 
reverse direction. Previously, Vermot and colleagues used the same gata2 morpholino to assess 
reverse flow (Vermot et al., 2009). They found that reverse flow is decreased in response to 





fraction by taking the total number of frames that exhibited reverse flow in their high speed 
videos and dividing that number by the total number of frames per cycle. Thus RFFVermot 
represents the fraction of time in one cardiac cycle during which reverse flow occurs. (Vermot 
et al., 2009). Note that this approach does not measure blood volume directly. Vermot and 
colleagues found that in non-injected wildtype embryos, 35% of the cardiac cycle contained 
reverse flow (Vermot et al., 2009). Therefore, reverse flow is a normal feature in early 
developmental stages, prior to valve development at the AVJ. By measuring the time 
dependent fraction (RFFVermot) we find that there is a significant decrease of reverse flow in 
response to lowered blood cell count (Figure 3.6a). However, we detected a reverse flow time 
fraction of 0.9% in the gata2 morpholino-injected embryos. Although this result is small it does 
result in a statistically significant result (p<0.05 relative to wildtype controls). In contrast, 
Vermot found, in gata2 morphants, 17% of the cardiac cycle exhibited reverse flow. The 
difference in the magnitude of the detected RFF was a surprise, given that the same 
morpholino and embryos of the same age were used. 
The potential limitation of measuring RFF according to time fractions is that it does not 
account for the size of the embryo, nor does it directly measure the amount of blood that is 
currently in the embryo. Johnson took advantage of the data inherent in the high speed videos 
to create a more accurate method for assessing RFF (Johnson et al., 2013a). Johnson measured 
reverse flow with reference to volume rather than time. He defined RFF as the amount of blood 
moving in the reverse direction in one cardiac cycle divided by the total accumulated volume in 
one cardiac cycle (Johnson et al., 2013b; Johnson et al., 2013a). We therefore measured 
RFFJohnson (Figure 3.6b). gata2 morpholino-injected controls exhibited a RFFJohnson of 0.005 
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(Figure 3.6b). The gata2 mismatch morpholino-injected control embryos and the non-injected 
wildtype control embryos however exhibited RFFsJohnson of 0.008 and 0.017 respectively (Figure 
3.6b). This method still shows a decrease in reverse flow however, no statistical significance 
was found between gata2 morpholino-injected embryos and the controls via ANOVA (p=0.158).  
  
 
Figure 3.6 – Average reverse flow fractions at the AVJ in gata2 morpholino-injected embryos. Data was collected 
from high speed video analyses. Error bars represent standard error of the mean. Values are unit-less ratios. A – 
Reverse flow fractions measured dependently on time of blood flow in one cardiac cycle. gata2 morpholino-
injected embryos (n=16) with a reverse flow time fraction of 0.009 show a significant decrease in reverse flow 
compared to the controls. gata2 mismatch morpholino-injected embryos (n=30) had a reverse flow time fraction 
of 0.093 and non-injected wildtype embryos (n=17), . . *p< . , Du s ethod. ANOVA p= . . B – Reverse 
flow fraction measured with volumes of blood through the AVJ. No significant difference was found in gata2 
morpholino-injected embryos with a reverse flow volume fraction of 0.005 compared to gata2 mismatch 
morpholino-injected e os  e e se flo  olu e f a tio  of .  a d o -i je ted ildt pe e os  e e se 
flow volume fraction of 0.017. ANOVA p=0.158. 
 
Reduced blood flow changes heart rate but does not affect the overall function of the embryonic 
heart 
 To understand how decreased blood viscosity affects heart rate and cardiac output, we 
analyzed high speed videos of the embryonic heart. Videos were taken ventrally at 48 hpf in 
gata2 morpholino-injected embryos, gata2 mismatch morpholino-injected embryos, and non-
injected wildtype embryos. Heart rate was measured by kymographs analyzed in a MATLAB 





2013a). In embryos with reduced blood viscosity, heart rate was significantly decreased in 
comparison to the non-injected wildtype embryos (Figure 3.7a). Surprisingly, heart rate was 
also significantly decreased in the gata2 mismatch morpholino-injected embryos, designed to 
serve as a gene-specific morpholino control.  
Using the high speed imaging analyses, the accumulated volume (volume of blood that 
has passed through the atrioventricular junction (AVJ) over one cardiac cycle) can also be 
measured to estimate the stroke volume, which is defined as the net volume of blood pumped 
to the body per stroke (Johnson et al., 2013a). Stroke volume is an estimate based on the 
velocity (speed) of the blood moving through the AVJ and the diameter at the AVJ (Johnson et 
al., 2013a).  
We hypothesized that lowering blood viscosity would alter stroke volume and therefore 
overall cardiac function of the heart. However, stroke volume in the gata2 morpholino-injected 
embryos was not significantly different from the stroke volume in the non-injected wildtype 
embryos or mismatch control embryos, based on ANOVA (p=0.553) (Figure 3.7b).  
Cardiac output is measured by multiplying stroke volume by heart rate. Cardiac output 
was not statistically different among the three treatments, based on ANOVA (p=0.766) (Figure 
3.7c). The similarity between the cardiac outputs of the three groups shows that a reduction in 






Decreasing the blood viscosity does not affect the velocity of blood through the atrioventricular 
junction 
Average normalized velocity represents a way to show the pattern of velocity at the AVJ 
varies across the cardiac cycle. In the graphs below, negative values indicate flow moving in the 
reverse direction. Overall, the velocity patterns in gata2 knockdown and flncb knockdown 
embryos appear to be highly similar to wildtype except for the portion of the cycle during which 
reverse flow is occurring.  
Changes in blood viscosity have no effect on average velocity through the AVJ (Figure 
3.8c). Average velocity is a calculation of the velocity over the entire cardiac cycle and is shown 
as a pattern through the cardiac cycle in Figure 3.8a. There is a slight increase in the gata2 
morpholino-injected embryos compared to the non-injected embryos and the gata2 mismatch 
morpholino-injected embryos, but this increase is not a statistically significant difference. 
Therefore, the decrease in blood viscosity had no effect on average velocity of the blood 
through the AVJ.  
To determine whether a specific part of the cycle shows differences between 
treatments, average velocity during 15-40% of the cardiac cycle was calculated (Figure 3.8d). A 
significant difference was found between gata2 morpholino injected embryos and non-injected 
wildtype control embryos (Tukey test, p<0.01). 
The blood velocity, measured at the center of the atrioventricular junction, is an 
additional indicator of functional efficacy in the embryonic heart. Maximum velocity represents 
the highest speed the blood cells are moving through the AVJ (Figure 3.8b or the peak of the 
graph in Figure 3.8a). Analysis of peak values by ANOVA showed that between groups, there is 
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no change in maximum velocity. Therefore, the decrease in blood viscosity had no effect on 
maximum velocity.  
 
Contractility changes result in an increase in reverse flow through the atrioventricular junction 
 To determine how a change in contractility affects reverse flow fraction at the AVJ, we 
measured reverse flow by both time and volume in flncb morpholino-injected embryos. We 
hypothesized that there would be an increase in reverse flow through the AVJ if the heart 
muscle contraction patterns were altered. The hypothesis was supported since flncb-depleted 
embryos exhibited a significant increase in reverse flow through the AVJ (Figure 3.9).  
 Using RFFVermot, a significant increase of reverse flow is found compared to controls 
(Figure 3.9a). Embryos with a change in contractility exhibited a RFFVermot of 0.283. The 25N 
morpholino-injected control embryos and the non-injected wildtype control embryo RFFsVermot 
were measured at 0.125 and 0.135 respectively. 
 When RFF was assessed by volume (RFFJohnson), the 25N morpholino-injected control 
embryos and the non-injected wildtype control embryo exhibited approximately 1.2 and 1.7% 
of the volume of blood moving in the reverse direction per cardiac cycle while flncb 
morpholino-injected embryos exhibit approximately 6% of the volume of blood moving in the 






A change in contractility reduces heart rate but does not change the overall cardiac output of 
the heart 
 In the next set of experiments, to understand how a change in contractility affects heart 
rate and cardiac output, we used the flnc morpholino, as described earlier, to measure heart 
rate and stroke volume. In flncb-depleted embryos, in response to a change in contractility, the 
heart rate decreased significantly (Figure 3.10a). The decrease in heart rate of flncb 
morpholino-injected embryos is statistically significant in comparison to both the non-injected 
wildtype embryos (p<0.001) and the 25N control morpholino-injected embryos (p=0.004).  
 Since flncb morpholino injections affect cardiac muscle structure, we hypothesized that 
cardiac function would be disrupted. However, our hypothesis was not supported as no 
statistically significant difference in stroke volume was found between groups (Figure 3.10b) 
(p=0.482).  
 Multiplying the heart rate and stroke volume together provides the cardiac output. 
Changing the heart rate by flncb knockdown did not show a difference in overall cardiac output 
of the heart (Figure 3.10c). The cardiac output for flncb morpholino-injected embryos were not 
statistically significant from the control groups (ANOVA p=0.241). Therefore, decreasing the 
heart rate by decreasing contractility by flncb depletion was not sufficient to affect the cardiac 








Figure 3.7 – Average means for heart rate, stroke volume, and cardiac output for gata2 knockdowns. Data was 
collected from high speed video analyses. Error bars represent standard error of the mean. A – In gata2 
morpholino-injected embryos, heart rate is decreased (155.2 bpm, n =16). gata2 mismatch morpholino-injected 
embryos also show a decrease in heart rate (162.7 bpm, n=30). Wildtype non-injected embryos displayed a heart 
rate of 193.5 bpm (n=17). *p<0.05, Tukey test. ANOVA p<0.001. B – gata2 morpholino-injected embryos had a 
stroke volume of 0.123 nl, gata2 mismatch morpholino-injected embryos had a stroke volume of 0.143 nl, and 
non-injected wildtype embryos had a stroke volume of 0.125 nl. No statistically significant difference was detected 
via ANOVA (p=0.553). C – Cardiac output measurements between gata2 morpholino-injected embryos, gata2 
mismatch morpholino-injected embryos, and non-injected wildtype embryos are similar. ANOVA p=0.766. gata2 
morpholino-injected embryos exhibited cardiac output at a rate of 18.9 nl/min. gata2 mismatch morpholino-
injected embryos had a cardiac output rate of 23.0 nl/min and non-injected wildtype embryos saw cardiac output 






    
 
 
Figure 3.8 – Average means for maximum velocity and average velocity through the AVJ in gata2 morpholino-
injected embryos. Data was collected from high speed video analyses. Error bars represent standard error of the 
mean. A – Average normalized velocity at the AVJ across the cardiac cycle. Patterns across groups remain the same 
except for times where reverse flow occurs. B – No difference was found in the maximum velocity through the AVJ 
in hearts from each group. Maximum velocity for gata2 morpholino-injected embryos was 11.3 mm/s (n=16). gata2 
mismatch morpholino-injected embryos had a velocity of 10.9 mm/s (n=30) and non-injected wildtype embryos, 
12.0 mm/s (n=17). ANOVA p=0.299. C – A slight increase was noted in the velocity of gata2 morpholino-injected 
embryos however no significant difference was present. Average velocity for gata2 morpholino-injected embryos 
was 5.3 mm/s. gata2 mismatch morpholino-injected embryos and non-injected wildtype embryos had average 
velocities of 4.5 mm/s and 3.9 mm/s respectively. ANOVA p=0.139. D – The average velocity 15%-40% through the 
cardiac cycle. gata2 morpholino-injected embryos and 25N morpholino-injected embryos exhibited negative 
velocity during this early portion of the cardiac cycle, but not as negative as non-injected wildtype embryos. gata2 
morpholino-injected embryos and 25N morpholino-injected embryos are statistically significantly different than 
non-injected wildtype embryos. ANOVA p<0.001. Average velocity of gata2 morpholino-injected embryos during 
this time point was -1.58 mm/s. Non-injected wildtype controls and 25N morpholino-injected embryos had velocities 






Figure 3.9 – Average reverse flow fractions at the AVJ in flncb morpholino-injected embryos. Data was collected 
from high speed video analyses. Error bars represent standard error of the mean. A – flncb morpholino-injected 
embryos exhibit a significant increase in reverse flow compared to controls. flncb morpholino-injected embryos had 
a reverse flow time fraction of 0.283 (n=19). 25N control morpholino-injected embryos saw a reverse flow time 
fraction of 0.125 (n=12) and non-injected wildtype embryos, 0.135 (n=17). *p< . , Du s ethod. ANOVA p= .  
B – The volume of blood moving in the reverse direction is much higher in flncb embryos than in control embryos. 
The flncb morpholino-injected embryos saw a reverse flow volume fraction of 0.06, 25N control morpholino-injected 
























Figure 3.10 – Average means for heart rate, stroke volume, and cardiac output for flncb knockdowns. Data was 
collected from high speed video analyses. Error bars represent standard error of the mean. A – Heart rate in flncb 
morpholino-injected embryos is significantly different from both non-injected embryos and 25N control morpholino-
injected embryos. flncb morpholino-injected embryos had a heart rate of 162.0 bpm (n=19). 25N control 
morpholino-injected embryos saw a heart rate of 180.9 bpm (n=12) and non-injected wildtype embryos, 193.5 bpm 
(n=17). *p<0.001, Tukey test. **p=0.004, Tukey test. ANOVA p<0.001. B – Stroke volumes between groups is not 
significantly different. flncb morpholino-injected embryos exhibited a stroke volume of 0.100 nl while 25N control 
morpholino-injected embryos had a stroke volume of 0.185 nl and non-injected wildtype embryos, 0.125 nl. ANOVA 
p=0.482. C – Measurements did not result in a significant difference in cardiac output. flncb morpholino-injected 
embryos saw a cardiac output rate of 16.0 nl/min, 25N control morpholino-injected embryos – 32.6 nl/min, and non-






Changing contractility of the embryonic heart changes the average velocity of blood through the 
atrioventricular junction 
 To observe whether or not a change in contractility affects the velocity of blood moving 
through the AVJ, we measured maximum velocity and average velocity. These measurements 
provide information as to how fast blood is moving through the embryonic heart (Figure 3.11b). 
We next plotted average velocity at the AVJ across the cardiac cycle. Overall patterns were 
similar except for the time in the cycle where reverse flow occurs (Figure 3.11a). An ANOVA test 
p value of 0.090 shows that there is no statistically significant difference between maximum 
velocity values.  
Consistent with the increased reverse flow fraction, the average velocity (over the entire 
cardiac cycle) of the blood in flncb morpholino-injected embryos was significantly lower than 
the control embryos (Figure 3.11c). To zoom in on the time in the cycle where reverse flow is 
occurring, average velocity from 15-40% of the cardiac cycle was calculated (Figure 3.11d). A 
Tukey test shows that flncb morpholino injected embryos and 25N morpholino-injected 





      
 
 
Figure 3.11 – Average means for maximum velocity and average velocity through the AVJ in flncb morpholino-
injected embryos. Data was collected from high speed video analyses. Error bars represent standard error of the 
mean. A – The average normalized velocity at the AVJ across the cardiac cycle. Patterns across groups remain the 
same except for times where reverse flow occurs. B – The means of maximum velocities are not significantly different 
across groups. flncb morpholino-injected embryos had a maximum velocity of 10.0 mm/s (n=19) while 25N control 
morpholino-injected embryos were at their maximum velocity at 11.3 mm/s (n=12). Non-injected wildtype embryos 
had the highest maximum velocity with 12.0 mm/s (n=17). ANOVA p=0.090. C – The average velocity across the AVJ 
in flncb morpholino-injected embryos differs from control embryos. flncb morpholino-injected embryos had an 
average velocity of -0.3 mm/s, 25N control morpholino-injected embryos – 4.6 mm/s, non-injected wildtype 
embryos – 3.9 mm/s. *p<0.05, Tukey test. ANOVA p<0.001. D – The average velocity 15%-40% through the cardiac 
cycle. flncb morpholino-injected embryos exhibited negative velocity during this early portion of the cardiac cycle. 
flncb morpholino-injected embryos and 25N morpholino-injected embryos are statistically significantly different 
than non-injected wildtype embryos. ANOVA p<0.001. Average velocity of flncb morpholino-injected embryos during 
this time point was -47.87 mm/s. Non-injected wildtype controls and 25N morpholino-injected embryos had 









Diameter of the atrioventricular junction does not change in response to alterations in 
hemodynamics, but diameter of atrium changes in response to lowered blood viscosity 
 To determine if morphological changes occurred as early as 48 hpf, we calculated 
diameter of the AVJ at 48 hpf. Our hypothesis for the gata2 morpholino-injected embryos was 
that the diameter would change because knocking down gata2 changes blood viscosity which 
may result in morphological defects. However, our results did not support this hypothesis 
because no change in diameter sizes throughout the groups was observed (Figure 3.12a).  
 Our hypothesis for the flncb morpholino-injected embryos was that AVJ diameter will 
change since we are knocking down the gene encoding a protein involved in muscle structure. 
No data yet shows that flncb is expressed in the AVJ, however by changing muscle structure of 
the whole heart, diameter could be affected. Our hypothesis was not supported since there 
was no change in diameter across the AVJ in flncb morpholino-injected embryos (Figure 3.12b). 
 To determine if diameter in the heart changes elsewhere in response to hemodynamics, 
the average atrial diameter was measured (Figure 3.13). flncb morpholino-injected embryos 
showed no change in atrial diameter while gata2 morpholino-injected embryos showed a 





Figure 3.12 – Average diameter across AVJ. Data was collected from high speed video analyses. A – Diameter across 
AVJ in gata2 morpholino-injected embryos and respective controls. Patterns across groups are very similar. B – 
Diameter across AVJ in flncb morpholino-injected embryos and respective controls. No changes in average diameters 
were observed.  
 
 
Figure 3.13 – Average atrium diameter. The average diameter across the atrium during the cardiac cycle. flncb 
morpholino-injected embryos show no significant difference in atrium diameter compared to non-injected wildtype 
controls. gata2 morpholino-injected embryos show a statistically significant difference compared to non-injected 
wildtype controls. Average atrium diameter of flncb morpholino-injected embryos, .  μm. Average atrium 
diameter of gata2 morpholino-i je ted e os, .  μ . A e age at iu  dia ete  of on-injected wildtype 









Flow rate through atrioventricular junction does not change in response to hemodynamic 
differences at 48 hours post fertilization, although shear rate experiences significant changes 
 To identify how flow patterns are affected by changes in hemodynamic forces, we 
estimated flow rate by multiplying blood velocity by the area of the AVJ. Flow rate is the speed 
at which flow is moving through a measured orifice, in this case the AVJ. This flow rate data is 
presented in nanoliters per minute or Q; the observed variation is shown across a cardiac cycle 
for both treatments (Figure 3.14). In gata2 morpholino-injected embryos (Figure 3.14a), flow 
rate was very similar to respective controls, and no significant differences were found when 
comparing the maximum Q. In flncb morpholino-injected embryos (Figure 3.14b), flow rate is 
also similar across the cycle, and no significant differences were found when comparing 
maximum Q values.   
 Shear rate is the biomechanical force applied to the walls of the orifice being measured. 
The flow rate (Q) represents a required coefficient for calculating shear rate. Shear rate (tau – τ  
is calculated by multiplying Q by 4 and then dividing by the radius cubed and multiplied by pi 
π  Figu e . ). Here, shear rate is used instead of shear stress because it eliminates the need 
fo  easu i g is osit . We a gue that is osit  μ  a ot e assu ed i  the e o i  hea t 
because of the varying blood flow that may occur at the AVJ due to the flow alteration 
treatments.  
We find that shear rate varies even in non-injected wildtype embryos as flow moves 
through the heart (Figure 3.16). To facilitate comparisons among the treatments, we chose to 
look at shear rate when the AVJ is open (Figure 3.17). The peaks observed relate to 
measurements when the AVJ diameter is small (i.e. AVJ is closing) and results in a large number 
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due to the radius being cubed. Both changes in hemodynamics respond to shear rate in the 
same manner. In gata2 morpholino-injected embryos, shear rate was significantly decreased 
compared to non-injected wildtype embryos when the AVJ was open. Similarly, flncb 
morpholino-injected embryos showed a significant decrease. These results represent a form of 
cardiac function different from our previous stroke volume and cardiac output results that were 
not significantly different.  
 
        
Figure 3.14 – Averaged flow rate patterns at AVJ across a cardiac cycle. Data was collected from high speed video 
analyses. A – Average flow rates for gata2 morpholino-injected embryos (n=16), gata2 mismatch morpholino-
injected embryos (n=30), and non-injected wildtype embryos (n=17). No significant difference was found at max Q 
between groups. ANOVA p=0.480. B – Average flow rates for flncb morpholino-injected embryos (n=19), 25N control 
morpholino-injected embryos (n=12), and non-injected wildtype embryos (n=17). No significant difference was 















Figure 3.16 – Shear rate patterns at the atrioventricular junction. Data was collected from high speed video 
analyses. A – Shear rate pattern of gata2 morpholino-injected embryos across an entire cardiac cycle. gata2 
knockdown shear rate is significantly lower than non-injected wildtype embryos (p<0.05, Tukey test). ANOVA 
p=0.009. B – This figure is a portion of Figure 3.16a from 0.4545 to 0.5555 of the cardiac cycle. Shear rate pattern of 
flncb morpholino-injected embryos across an entire cardiac cycle. flncb morpholino-injected embryos exhibit a much 























Figure 3.17 – Shear rate when the atrioventricular junction is open. Data was collected from high speed video 
analyses. A – Shear rate pattern through the AVJ when the AVJ is open in gata2 morpholino-injected embryos. gata2 
morpholino-injected embryos (and gata2 mismatch morpholino-injected embryos) exhibit a shear rate significantly 
lower than non-injected wildtype embryos (p<0.05, Tukey test). ANOVA p<0.001. Ai – Average values from A. B – 
Shear rate pattern through the AVJ when the AVJ is open in flncb morpholino-injected embryos. flncb morpholino-
injected embryos exhibit a different pattern and an overall lower shear rate than non-injected wildtype embryos 















Lowered blood viscosity impacts cmlc2 and klf2a expression levels 
 In order to investigate the response of potential flow response genes to lowered blood 
viscosity, we utilized qPCR. The graph in Figure 3.18a indicates transcript copy numbers per 
microgram of RNA present for each gene in the gata2 morpholino-injected embryos (red bars) 
versus the control, non-injected wildtype embryos (light grey bars). Using a standard curve and 
absolute quantification, we detected a significant difference in copy numbers of klf4 and klf2a 
in gata2 morpholino-injected embryos versus non-injected wildtype embryos (p<0.05 – klf2a, 
p<0.001 – klf4) (Figure 3.18a). Values are represented in Table 3.1.  
In order to compare how lowered blood viscosity affected expression levels of these 
genes, we utilized relative quantification (Figure 3.18b). Relative quantification was used to 
take into account the non-injected control gene expression levels directly compared to the 
experimental expression levels. This graph shows expression ratios of each gene in comparison 
to the non-injected control. Values are represented in Table 3.2. Lowered blood viscosity results 
in a decrease in expression of both cmlc2 and klf2a (p=0.03, both) (Figure 3.18a). No significant 

















    
 
Figure 3.18 – Absolute and relative quantification on embryonic hearts with lowered blood viscosity at 56 hpf. 
Error bars represent standard error of the mean. Non-injected embryos n=10. Injected embryos n=11. A – Absolute 
quantification of gata2 morpholino-injected embryos and non-injected wildtype embryos. Copies of cDNA per 
microgram of RNA per each gene and respective control. Copy numbers of klf4 and klf2a are significantly different 
in gata2 morpholino-injected embryos than in non-injected wildtype control embryos. *p<0.05, **p<0.001, Wel h s 
t-test. B – Relative quantification of gata2 morpholino-injected embryos and non-injected wildtype embryos. 
Expression ratio of genes and respective controls. Expression ratios of cmlc2 and klf2a are significantly decreased in 












Changes in cardiac contractility impact expression levels of klf2a 
 Next, we investigated expression levels of our target genes in response to a change in 
cardiac contractility. Using absolute quantification, we found no significant difference in flncb 
morpholino-injected embryos versus non-injected wildtype embryos (Figure 3.19a). Values for 
copy numbers are represented in Table 3.1.  
Using relative quantification, we identified that changes in cardiac contractility result in 
a decrease in expression of klf2a (p=0.04) (Figure 3.19b). Values for expression ratios are 













Figure 3.19 – Absolute and relative quantification of embryonic hearts with defective contractility at 56 hpf. Error 
bars represent standard error of the mean. Non-injected embryos n=10. Injected embryos n=11. A – Absolute 
quantification of flncb morpholino-injected embryos and non-injected wildtype embryos. Copies of cDNA per 
microgram of RNA per each gene and respective control. No sig ifi a t diffe e e as oted  Wel h s t-test. B – 
Relative quantification of flncb morpholino-injected embryos and non-injected wildtype embryos. Expression ratio 
of genes and respective controls. klf2a expression is significantly decreased in flncb morpholino-injected embryos 
















Table 3.1 – Mean copy numbers for absolute quantification.  
 
 cmlc2 klf4 klf2a klf2b ef1a 
Mean copy number (non-injected) 836179.8 54289.2 64251.0 59269.2 10632931.1 
      
Mean copy number (gata2) 1475948.9 752.0 991941.5 56027.9 22364784.8 
      
Mean copy number (flncb) 91908.5 141817.7 266503.0 20778.8 52137701.6 
  
 
Table 3.2 – Mean expression ratios for relative quantification. 
 
 cmlc2 klf4 klf2a klf2b 
Mean expression ratio (non-injected) 2.272062 7.551815 5.753338 6.517471 
     
Mean expression ratio (gata2) 0.961174 12.62508 1.586341 3.273325 
     




































Expression patterns of klf2a, klf2b, and klf4 
 One of the main goals of this study was to identify cardiac expression of klf2a, klf2b, and 
klf4. First, to verify that these genes were expressed at time points in the embryo that were 
relevant to heart development, expression in whole embryos from time points from two hours 
post fertilization to 72 hours post fertilization was investigated (Figure 3.1). All genes were 
expressed at two hours post fertilization (around the time of the zebrafish mid-blastula 
transition) which leads us to believe that these genes are transcribed at the start of 
development. This is important to know because cardiac progenitors start moving towards the 
midline to their final destination in the anterior lateral plate mesoderm (ALPM) at about five 
hours post fertilization (Bakkers, 2011). The endocardium and hematopoietic cells of the 
primitive myeloid lineage are also formed from the ALPM (Bakkers, 2011). Therefore, it is 
possible that these genes are involved in early heart development starting with the cardiac 
progenitors. An interesting future study would be to see if the target genes klf2a, klf2b, and klf4 
are expressed in the ALPM at early stages to see if they are involved in early heart development 
stages as well as the later stages that we investigate here. 
Our next goal was to identify the specific times and locations in the heart that klf2a, 
klf2b, and klf4 were expressed. We looked at embryonic cardiac expression at 24, 36, 48, 56, 
72, and 96 hours post fertilization via RT-PCR and in situ hybridization. We found that at almost 
all stages investigated, cardiac expression was found in all genes (Figure 3.2a). Specifically, 
expression in the AVJ was noted for klf2a and klf2b. cmlc2, which encodes a protein involved in 
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cardiac myofibril assembly, was chosen as a control in the in situ hybridizations because it is 
robustly expressed throughout the heart at all stages (Yelon et al., 2000). The expression of 
cmlc2 allows for identification of the shape of the heart at respective stages which can be used 
to determine location of the AVJ at each stage.  
klf2a is broadly expressed during cardiac development, which is consistent with 
previous work (Dekker et al., 2002) (Figure 3.3). Expression of klf2a does not constrict to the 
AVJ until 36 hours post fertilization. From then on, klf2a expression is detectable only in the 
AVJ. klf2a is known to be expressed in the heart and is also known to be expressed in the AVJ 
(Vermot et al., 2009). Our work confirms that klf2a is expressed in the AVJ and is important 
because previous studies correlate misexpression of klf2a with cardiac morphologies (Wang et 
al., 2011; Dietrich et al., 2014; Heckel et al., 2015; Renz et al., 2015).  
klf2b was not expressed in the heart at 24 and 36 hours post fertilization, as detected by 
RT-PCR. This expression pattern mimicked what we found in the in situ hybridizations and 
indicates that klf2b is not involved in early heart development, but is involved in the later heart 
development stages. Because of the potential functional redundancy with klf2a, we 
investigated the location of klf2b expression in the heart. We found cardiac expression for klf2b 
located mainly in the ventricle and AVJ. This expression pattern is a novel finding because 
currently all that is known about klf2b is its involvement in embryonic patterning (Kotkamp et 
al., 2014). 
To investigate whether or not cardiac expression of klf4 is actually from heart and not 
blood, we depleted blood in embryos. These gata2 depleted embryos have no blood circulating 
at 72 and 96 hours post fertilization. At these times klf4 is expressed in the heart (Figure 3.2b) 
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which verifies that the RT-PCR expression in Figure 3.2a is partially due to true cardiac 
expression. We found no cardiac expression of klf4 in the heart at 24 hours post fertilization via 
in situ hybridization. However cardiac expression does occur at 24 hours post fertilization via 
RT-PCR. This discrepancy most likely reflects the lower sensitivity of in situ hybridization relative 
to RT-PCR. Cardiac expression is evident at 48 and 56 hours post fertilization, however, and may 
represent both cardiac expression and blood expression. Although only diffuse cardiac 
expression of klf4 is observed, we hypothesize that it is not detectable by in situ hybridization 
and is still a potential flow response gene.  
After verifying expression patterns of the klf-family genes, the next set of experiments 
tested whether these genes were flow response genes. To investigate, we changed the 
hemodynamics in the embryonic heart. We lowered blood viscosity by depleting gata2, and we 
reduced contractility of the heart by depleting flncb. By knocking down gata2, the number of 
blood cells that are circulating throughout the embryonic vasculature is reduced. Knocking 
down flncb results in a change in cardiac muscle structure. These knockdowns provide an 
avenue to investigate altered hemodynamics in the embryonic heart via high speed imaging 
and the changes in gene expression of three key klf candidate flow response genes.  
To identify the effect of lowered blood viscosity on embryonic survival, we observed the 
embryos for ten days. Only 19.2 % of gata2 morpholino-injected embryos died by day ten 
(Figure 3.4a). This percentage was similar to the gata2 mismatch morpholino-injected embryos, 
where 21.3% died by day ten. This similarity suggests a possible contribution from off target 
effects of the mismatch morpholino. In the literature, approximately 15-20% of morpholinos 
have some degree of toxic effects, leading to death (Ekker and Larson, 2001). If death rate is 
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too high, a p53 morpholino can be added to ameliorate off target and apoptotic effects (Gerety 
and Wilkinson, 2011). In contrast, 6.8% of non-injected wildtype embryos died, which indicates 
that some embryos do not survive due to factors not related to morpholino injection. Based on 
the results here, we conclude that lowered blood viscosity does not severely affect survival 
before day ten. This result coincides with the fact that embryos can survive with a non-
functioning cardiovascular system until about day five through seven (Kopp et al., 2010; Hoage 
et al., 2012). The developing embryos obtain oxygen through diffusion so the embryos have an 
oxygen source if no blood is circulating. Since these embryos survive for a relatively long time it 
allows researchers to investigate the impact of lowered blood viscosity during major steps in 
cardiac development without the complications of hypoxia.  
In comparison, flncb morpholino-injected embryos saw 37.7% death at day ten (Figure 
3.5a). The 25N control morpholino-injected embryos had 14.3% death and the non-injected 
wildtype embryos had 0% death. The importance here is the fact that the control injected 
embryos here survived better and shows that a randomly assigned base pair morpholino (25N-
MO) has less off target effects when compared to mismatch morpholinos that are only five base 
pairs different than their target gene. 37.7% death is higher than what was observed in the 
gata2 morpholino-injected embryos. This death rate indicates that the flncb depletion is more 
detrimental to the embryo, than simple injection which could mean that flncb promotes the 
overall survival of the heart. 
In order to see what effects decreased blood viscosity and changes in contractility have 
on heart development through valve morphogenesis stages, we observed hearts at four days 
post fertilization.  Multiple phenotypes were seen at day four in gata2 morpholino-injected 
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embryos and 39.7% of these embryos exhibited a cardiac phenotype (Figure 3.4b). Some 
embryos exhibited more than one phenotype, and where the most common phenotypes were 
cardiac edema (38.3%) and a change in blood flow either no blood flow (27.7%) or reduced 
blood flow (7.8%). These two are common phenotypes in gata2 knockdowns have been seen in 
previous work (Vermot et al., 2009). Some morphological phenotypes included stringy heart 
(10.0%), non-compact heart (14.1%), and silent ventricles (5.0%). Stringy heart is the term to 
describe a chamber (usually the atrium) that is stretched out and visibly looks like a string. 
Sometimes waves of contractions move through the stringy chambers, but often they are silent 
(non-contracting). This phenotype usually will result in death as early as day five, once the 
embryo starts relying on blood to transport oxygen. Silent hearts will not be able to pump blood 
sufficiently to the rest of the body. We defined the non-compact heart as a heart that was not 
fully looped and resemble a younger stage of development. The embryos with this phenotype 
would probably survive, as the heart is still able to pump blood through albeit less efficiently. 
5.0% of embryos had a silent ventricle and while these ventricles may look normal structurally, 
they are not pumping blood to the rest of the body. These embryos will also perish around day 
five. In summary, lowered blood viscosity results in cardiac morphologies that alter the way 
blood is circulated to the rest of the body. 
In the flncb morpholino-injected embryos, the most common cardiac phenotypes 
observed were a change in blood flow (24.8% - no blood flow) and a silent ventricle (14.7%). 
Previous reports of flncb knockdowns focused on skeletal muscle describing the failure of both 
slow and fast twitch muscle fibers (Ruparelia et al., 2012). We expected to see a change in 
contraction, including the possibility of silent ventricles. As mentioned with the gata2 
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morpholino-injected embryos, a silent ventricle will result in early death around day five. A 
surprising phenotype was the decrease in blood flow which was expected in the gata2 
morpholino-injected embryos, but not necessarily predictable for flncb depletion. A change in 
blood flow most likely comes from pooling in the body because the heart is not contracting well 
enough to pump blood efficiently through the entire circulatory system. These phenotypes are 
useful for observing the overall comparative effects are of lowered blood viscosity and changes 
in contractility.  
 
Hemodynamics and the embryonic zebrafish heart 
In order to quantify the effects of altered hemodynamic factors on heart function, 
videos of 48 hours post fertilization embryos were analyzed. These videos provide reverse flow 
and shear rate data and also data such as heart rate, stroke volume, and velocity of the blood, 
all of which will be correlated with gene expression changes. 
Heart rate in a non-injected wildtype embryo starts at around 25 beats per minute at 24 
hours post fertilization and peaks at 230-250 beats per minute at five days post fertilization 
(Schwerte, 2009). We observed the embryos at 48 hours post fertilization and recorded an 
average heart rate of 193.5 beats per minute. Our findings are higher than previously published 
heart rates. In 1999, Barrionuevo and Burggren recorded embryonic heart rate (prior to 
hatching) at approximately 150 beats per minute (Barrionuevo and Burggren, 1999). In 2013, 
however, using more modern high speed imaging, Dalman and colleagues recorded heart rate 
in 48 hours post fertilization embryos at approximately 130 beats per minute (Dalman et al., 
2013). While neither method describes the frame rate of their high speed imaging, our images 
66 
 
are captured in 1500 frames per second videos and calculated with sophisticated MATLAB 
software. Using our very accurate heart rate calculations we saw a decrease in heart rate in 
embryos with lowered blood viscosity and in embryos with altered cardiac contractility. 
Embryos with lowered blood viscosity exhibited an average heart rate of 155.2 beats per 
minute and embryos with altered cardiac contractility exhibited an average heart rate of 162.0 
beats per minute. This approximate 17% decrease in heart rate is statistically significant and 
demonstrates that both blood viscosity and muscle structure are important in maintaining a 
functioning heart.  
While thinking about function, the next question to ask is how does the lower heart rate 
affect the overall output of the heart? Stroke volume is the amount of blood that is pumped 
through the heart to the body in one cycle of cardiac contraction. Cardiac output is the product 
obtained from multiplying stroke volume by heart rate. Cardiac output may be considered a 
rubric for overall cardiac function of the heart. Average cardiac output for gata2 morpholino-
injected embryos was 18.9 nl/min, which shows that these hearts are able to pump 18.9 
nanoliters of blood through the heart to the body in one minute. Non-injected wildtype 
embryos exhibited an average cardiac output of 24.4 nl/min. This is higher than the value 
observed in embryos with lowered blood viscosity, but this difference was not statistically 
significant. Embryos with altered cardiac contractility also saw a decrease in cardiac output, but 
nothing significantly different. These findings show that even though heart rate was changed 
because of the effects of altered viscosity and contractility, the heart was still functioning as a 
normal pump. Findings like this are important to show that hearts can still function with 
changes in hemodynamics. These findings could also explain why the morphants have a survival 
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rate that is not severely reduced. The hearts are functioning with the ability to maintain 
circulation and compensate for the lowered heart rates, lowered blood viscosity, and a change 
in muscle structure.   
Since the change in blood viscosity and change in muscle structure did not affect overall 
cardiac output of the heart, yet a range of cardiac phenotypes was observed in many of the 
embryos, we hypothesized that other factors, like reverse flow, were changing. Vermot and 
colleagues have shown that in gata2 morpholino-injected embryos, the fraction of the cardiac 
cycle exhibiting reverse flow is decreased (Vermot et al., 2009). Based our video data, we 
redefined reverse flow as the volume of blood that is moving in the reverse direction divided by 
the total volume of blood, making this measurement a unit-less fraction. In contrast, Vermot 
measured reverse flow as a fraction of time, the length of time the blood is moving in the 
reverse direction divided by the total length of the cardiac cycle (Vermot et al., 2009). 
We measured reverse flow with time dependent fractions and volume dependent 
fractions.  In embryos with lowered blood viscosity, we saw a decrease in reverse flow in both 
measurements (Figure 3.6). With our way of defining reverse flow using the volume fraction, 
we did not find a statistically significant change. However, there was still a difference of 1.2%, 
stating that the embryos with lowered blood viscosity have 1.2% less volume of blood moving 
in the reverse direction compared to the non-injected wildtype embryos. This result is 
consistent with the data generated by Vermot in that the same trend is found (a decrease in 
RFF), although the magnitude of RFF in both the wildtype and knockdown embryos was much 
less. Nevertheless, we did see a statistically significant difference in the time fractions between 
the two control groups and the gata2 morpholino-injected embryos. Embryos with lowered 
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blood viscosity had 1.0% of the time in the cardiac cycle containing reverse flow. In the non-
injected wildtype embryos average the reverse flow fraction (time) was 13.5% of the cycle 
containing reverse flow. 
Embryos with altered cardiac contractility had an increase in reverse flow (Figure 3.9). 
This increase was found in both the time fraction and the volume fraction. Using the volume 
fraction measurements, flncb morpholino-injected embryos produced a reverse flow fraction of 
6% while non-injected wildtype embryos saw a reverse flow fraction of 1.7%. This difference is 
statistically significant and reassures us that flncb knockdown does result in an increase in 
reverse flow. Measuring by the time fraction also shows the same trend. Non-injected wildtype 
embryos have a reverse flow fraction of 13.5% while flncb morpholino-injected embryos have a 
reverse flow fraction of 28.3%, which is also a statistically significant difference.  
By comparing the two types of fractions (volume and time), we can see that they both 
show the same trends. However, measuring reverse flow using volume is advantageous. An 
advantage to this approach is that it measures a characteristic (volume of blood within the 
heart, moving retrogradely) that is more relatable to the phenotypes being observed. Viscosity 
of the blood is affected by gata2 morpholino knockdown (which correlates with a lower 
volume), and flncb morpholino knockdown embryos exhibit decreases in blood flow (also 
correlating with lower blood volume). Another advantage is that measuring with volume will 
account for the size of the embryo. By taking the size of the heart into account, the data can be 
more accurately portrayed. Measuring reverse flow as a fraction of time could be advantageous 
in morphants that are affected by timing of the contraction (i.e. arrhythmia). A limitation to 
measuring with time is that it does not account for the size of the embryo or the amount of 
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blood actually moving through the heart. Therefore, future studies should be focused on the 
volume fraction rather than the time fraction, which will allow for a better portrayal of reverse 
flow in the embryonic heart. 
After discussing the pros and cons of the fractions, we need to think about how reverse 
flow is affected by lowered blood viscosity. gata2 is a hematopoietic transcription factor that is 
responsible for controlling early hematopoiesis (Galloway et al., 2005). In gata2 morpholino-
injected embryos, without a high number of blood cells moving through the heart, cells at the 
AVJ are freer to move through and there is less pressure to push cells backwards when the 
ventricle contracts. A decrease in viscosity affects heart development, and does not allow for 
the correct formation of valves in the AVJ (Vermot et al., 2009). When flow is perturbed, 
signaling of the correct pathways does not occur and therefore development of the valves is 
affected. An ongoing important question in the field is to identify the genes that are 
misregulated with a disruption of flow. 
flncb is a gene encoding a sarcomeric protein that when knocked down, results in 
decreased skeletal and cardiac muscle integrity (Ruparelia et al., 2012). When a sarcomeric 
protein is disrupted, contraction of the respective muscle is affected. Without regular 
contractions in the heart, blood flow is predicted to change. Consistent with this prediction, the 
hearts of flncb morpholino-injected embryos exhibited an increase in reverse flow. In these 
embryos, hearts had a decreased heart rate and altered cardiac contractility, which resulted in 
allowing more blood to flow back through the AVJ during ventricle contraction. This same trend 
was also seen in work involving anesthetizing the embryo (Johnson et al., 2013a). Johnson 
anesthetized embryos with tricaine and recorded a RFF of 80% (Johnson et al., 2013a). While 
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tricaine does not have the same effect as depletion of a sarcomeric protein, it does relax 
muscles, which accounts for an alteration in contraction. The alteration in contraction results in 
lowered heart rate in both cases (anesthetized and flncb knockdown), however flncb 
knockdown does not result in a change in cardiac output while tricaine results in a significant 
decrease in cardiac output (28.4 nl/min in wildtype to 3.1 nl/min in anesthetized) (Johnson et 
al., 2013a). This comparison helps us understand that flncb does not influence the overall 
cardiac output of the heart instead only alters muscle contraction which slightly alters blood 
flow in the developing heart. Future studies can use this information to focus on the exact 
mechanism.  
With our video analyses, we are also able to determine diameter of the AVJ and the 
velocity of the blood through the AVJ. In embryos with lowered blood viscosity, we 
hypothesized that the diameter of the AVJ would not change. Later in development when flow 
knockdown is affecting valve development would be a time when one could suggest a change in 
AVJ diameter. Our hypothesis was supported as we saw no change in AVJ diameter at 48 hours 
post fertilization in embryos with lowered blood viscosity and altered cardiac contractility 
(Figure 3.12a).  
Surprisingly, diameter of the AVJ in embryos with altered cardiac contractility was not 
affected. We hypothesized that since muscle structure was being perturbed, that the size or 
shape of the heart would change. However, the diameters of the AVJs in each group were very 
similar (Figure 3.12b). This does not mean that the size of other orifices in the heart (atrial inlet, 
outflow tract) have not changed, but our only objective in this study is measuring the AVJ. Our 
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high speed videos and analyses could be used to determine the impact on atrial inlet and 
outflow tract.  
The non-significant findings of diameter differences between treatments should not go 
unremarked because they show us that lowering blood viscosity and altering cardiac 
contractility do not drastically affect the shape or size of the AVJ through 48 hpf, and does not 
ultimately lead to lethality in more than 20% of knockdown embryos. More work should be 
done to make this observation conclusive, but these findings can provide the framework for 
future studies. 
We hypothesized that diameter may change elsewhere in the heart other than the AVJ. 
To observe this, the average diameter of the atrium was measured throughout the cardiac cycle 
(Figure 3.13). flncb morpholino-injected embryos showed no significant difference when 
compared to controls, however gata2 morpholino-injected embryos showed a statistically 
significant difference compared to non-injected wildtype embryos. These results show that 
blood viscosity must play a role in the ballooning of the atrial chamber, while contractility does 
not affect the overall shape and morphology of the AVJ or atrium.  
Velocity of the blood is measured usi g Joh so s o el al ulatio s (Johnson et al., 
2013a). In embryos with altered cardiac contractility, average velocity is significantly different 
than in control embryos. The average velocity for embryos with altered cardiac contractility is 
negative (-0.3 mm/s) while non-injected and control embryos have larger positive values for 
velocity (3.9 mm/s and 4.6 mm/s respectively). The negative velocity shown represents flow 
moving in the reverse direction. The current data do not pinpoint any one part of the cycle that 
is responsible for this since this value is averaged from the whole cardiac cycle. Nevertheless, it 
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corresponds with the results from the reverse flow fraction measurements. Embryos with 
altered contractility had a greater reverse flow fraction and a negative number for the average 
velocity, suggesting overall that the amount of time that blood is spent moving in the reverse 
direction in the AVJ is notable.  
In order to pinpoint the part of the cycle that is responsible for blood moving in the 
reverse direction, the average velocity from 15-45% of the cardiac cycle was calculated. Times 
were chosen based on the velocities shown during the whole cardiac cycle. Average velocity for 
flncb morpholino-injected embryos was -36.90 mm/s while non-injected wildtype embryos 
exhibited an average velocity of -5.88 mm/s. Tukey tests show that this is a significant 
difference. These values were calculated to show that the early part of the cycle where blood is 
moving from the atrium to the ventricle is where the direction of blood is mostly in reverse.  
Embryos with lowered blood viscosity exhibited no statistically significant change in 
maximum or average velocity. With a change in blood viscosity one could hypothesize that 
velocity of the remaining blood cells would increase. While there was no statistically significant 
difference, the trend in Figure 3.8b did show a slight increase from non-injected wildtype 
embryos (4.5 mm/s) to gata2 morpholino-injected embryos (5.3 mm/s). This finding is still 
interesting because it shows a trend in the direction that was expected, just not a significant 
trend.  
Along with reverse flow, forward flow and shear stress through the AVJ are important 
factors in this study. Embryos with lowered blood viscosity and those with altered cardiac 
contraction show similar flow patterns and no significant difference was found at maximum 
flow (Figure 3.14). Since flow is the amount of blood that is moving through the heart in one 
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minute, we can use this information to calculate shear rate. Shear rate is used instead of shear 
stress because we cannot reliably account for viscosity in each of the treatments. gata2 
knockdown effectively alters the viscosity of the blood, therefore changing the velocity of the 
fluid that is being measured through the AVJ; for this reason, we cannot assume a constant 
viscosity across measurements. However, using the calculation in Figure 3.15 to calculate shear 
rate, shear rate patterns were decreased (Figure 3.16). The peaks that are visible result from 
when the radius of the AVJ gets too small (i.e. when AVJ is closing). Embryos with lowered 
blood viscosity did exhibit a significantly lower overall shear rate (p<0.05) (Figure 3.16a).  
Looking at the whole cardiac cycle makes it hard to see significant differences by eye. 
When we look at shear rate only when the AVJ is open, embryos with lowered blood viscosity 
have a lower shear rate than non-injected wildtype embryos (Figure 3.17a). One thing to keep 
in mind is that the gata2 mismatch morpholino-injected embryos are also significantly different 
from non-injected wildtype embryos when the AVJ is open. This result could be another artifact 
of using the mismatch morpholino as a control. We did hypothesize that lowered blood 
viscosity would result in lowered shear rate because lowering blood viscosity reduces the 
amount of shear that is passing through the orifice.  
We hypothesized that embryos with altered cardiac contractility would exhibit an 
increase in shear rate. Our results did not support that hypothesis, as flncb morpholino-injected 
embryos exhibited a statistically significantly lower shear rate than non-injected wildtype 
embryos (Figure 3.16b). When the AVJ is open, the controls demonstrated similar trends of 
increasing in shear as the AVJ closes. Embryos with altered cardiac contractility decrease in 
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shear rate as the AVJ closes. We can conclude from this data that as reverse flow increases, 
shear rate decreases.   
The shear rate in both sets of treated embryos is significantly lower. Previous work 
reports that shear rate decreases as the embryo ages from three days post fertilization to six 
days post fertilization (Jamison et al., 2013). The embryos in this study are analyzed at two days 
post fertilization and already have significantly lower shear rate than non-injected wildtype 
control embryos. By starting at a lower shear rate, morphological consequences may occur. It is 
possible that genes that are altered by shear rate are turned on or off too soon because of the 
early decrease in shear rate. Future work can identify timing of the gene expression changes 
and the downstream targets of these genes. 
 
klf2a, klf2b, and klf4 expression levels in response to changes in hemodynamics 
To determine how the target genes klf2a, klf2b, and klf4 respond to changes in 
hemodynamics, we investigated the gene expression levels via absolute and relative 
quantification. Our findings show significant changes in expression levels of klf2a and cmlc2 in 
embryos with lowered blood viscosity and altered cardiac contractility. klf2a is known to be 
down regulated in response to gata2 knockdown (Vermot et al., 2009). We hypothesized since 
klf2b and klf4 are similar in sequence and expression to klf2a, klf2b and klf4 will be down 
regulated in embryos with lowered blood viscosity. In embryos with altered cardiac 
contractility, we hypothesized klf2a, klf2b, and klf4 would show an increase in expression levels. 
First, we determined the transcript copy numbers for each gene via absolute 
quantification (Figure 3.18a, 3.19a). This type of quantification compares the number of copies 
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of cDNA obtained from one microgram of mRNA. klf4 and klf2a exhibited statistically significant 
changes in transcript copy number in embryonic hearts with lowered blood viscosity than 
control embryos. klf4 exhibited a decrease in transcript copy numbers while klf2a exhibited a 
slight increase in transcript copy numbers. All other genes had no significant differences in 
comparisons of transcript copy numbers.  
Utilizing these numbers, relative quantification was explored to examine the effects of 
lowered blood viscosity on the expression levels of our target genes (Figure 3.18b). In embryos 
with lowered blood viscosity, no significant differences were found in klf4 and klf2b. 
In contrast, klf2a and cmlc2 both showed significant decreases in expression levels with 
lowered blood viscosity. klf2a is an internal positive control to verify that we are seeing results 
reported in previous work. The expression level of klf2a decreased as was previously shown 
(Vermot et al., 2009) and not only verifies that klf2a is in fact a flow response gene, but it 
reassures us that our analyses are correct.  
We decided to investigate cmlc2 along with our target genes because cmlc2 is expressed 
robustly throughout heart development and is involved in cardiac myofibril assembly 
(ZFIN.org), although cmlc2 was not predicted to be a flow response gene. However, looking at 
its expression levels can tell us if the heart is experiencing structural changes. In response to 
lowered blood viscosity, we observed a significant decrease in cmlc2 expression. Putting this 
information together suggests that decreasing the blood viscosity in the heart does impact 
cardiac muscle cells, and might affect sarcomere structure or integrity. This result is novel, 
linking the hemodynamics to changes in the structure and development of the embryonic 
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heart. To further investigate, one could use immunohistochemistry or electron microscopy to 
identify changes in cardiac structure in more detail. 
No significant differences were found via absolute quantification of the target genes in 
embryos with altered cardiac contractility compared to control embryos (Figure 3.19a). These 
findings once again reflect the copy numbers of cDNA for every microgram of RNA. In order to 
compare expression levels between control embryos and embryos with altered contractility, we 
must use relative quantification. cmlc2, klf2b, and klf4 expression did not exhibit statistically 
significant results using relative quantification, but klf2a expression was significantly decreased. 
klf2a was previously described as a flow response gene, but our study is the first to 
investigate the transcriptional response to knockdown of a sarcomeric protein, flncb. In 
embryos with altered cardiac contractility, we find klf2a expression to be significantly 
decreased (Figure 3.19b). This finding is important because it suggests that klf2a may respond 
to shear rate and not reverse flow as previously thought (Vermot et al., 2009). As a reminder, 
reverse flow increased in embryos with altered cardiac contractility. Previously it was thought 
that klf2a responded more to reverse flow than shear rate (Vermot et al., 2009). The current 
results show a decrease in klf2a expression each time shear rate is significantly decreased (but 
not reverse flow). These esults suppo t Ve ot s data that klf2a expression decreases in 
response to lowered blood viscosity. However, Vermot concluded that response to be due to 
changes in reverse flow alone. Out gata2 knockdown results along with our flncb knockdown 
results show that shear stress is the determining factor in the changes in klf2a expression 
levels. This conclusion can be made by observing the reverse flow fractions and shear rates in 
the flncb morpholino injected embryos. To further clarify that shear rate is the determining 
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factor in changes in klf2a expression levels, a future study could increase shear rate and 
measure klf2a expression. These results also reiterate that klf2a is a flow response gene and in 
particular, suggests that klf2a may function specifically as a shear rate response gene. 
 




↓ hea t ate ↓ e e se 
flow 
↓ shea  ate ↓ klf2a ↓ klf2b ↑ klf4 ↓ cmlc2 
Change in 
contractility 
↓ hea t ate ↑ e e se 
flow 
↓ shea  ate ↓ klf2a ↑ klf2b ↑ klf4 ↓ cmlc2 
 
To conclude, hemodynamic properties of the embryonic heart are affected by depletion 
of two very different factors, a hematopoietic transcription factor and a sarcomeric cardiac 
muscle protein. The changes in hemodynamics result in morphological defects, decreased heart 
rate, and alterations to reverse flow and shear rate. As reviewed (also shown in Table 4.1), 
lowered blood viscosity results in lower heart rate, lower reverse flow and a decrease in shear 
rate compared to control embryos. Embryos with altered cardiac contraction exhibited lower 
heart rate, increased reverse flow and a lower shear rate than control embryos. To connect 
hemodynamics with changes in gene expression, we have demonstrated that klf2a transcription 
responds to shear rate rather than reverse flow. Our data also suggest that cmlc2 responds to 
endocardial shear which in turn promotes restructuring of the heart. More work will be 
necessary to confirm this, but results could lead to insights on cardiac morphologies. A final 
important conclusion is that our three target genes klf2a, klf2b, and klf4 are not functionally 
redundant. While klf4 and klf2b may still have flow response qualities, they are not significantly 








Fish Care  
 All zebrafish were kept at 27-28°C. Adult zebrafish were fed brine and flakes daily and 
a ies e e fed )iegle s li uid diet. Ba  ze afish e e i t odu ed i to the s ste  at fi e 
days post fertilization. They were introduced initially into no-flow water, then moved to slow 
flow at 14 days, and regular flow at three months. Babies were fed liquid diet until three 
months, but flakes were added to their diet at 14 days. Breeding began as early as three 
months post fertilization. Fish lines were replenished after fish stopped breeding or they were 
aged two years. Old fish were euthanized humanely according to the guidelines approved by 
the Animal Care and Use Committee. The wild type lines used were TL (Tupfel Long Fin) and 
WIK. Tg(cmlc2:GFP) homozygous fish were crossed with wild type lines for experimental use. All 
embryos were developmentally staged according to Kimmel et al (Kimmel et al., 1995). 
 
Dechorionation and Fixation of Embryos 
 Zebrafish embryos were dechorionated using Pronase® a protease extracted from 
Streptomyces grisius (CALBIOCHEM). Pronase® degrades proteins in the chorion. Pronase® was 
used at a stock concentration of five mg/ml. Two milliliters of Pronase® was added to a petri 
dish of embryos in approximately 20 milliliters of E3 water. Embryos were swirled around 
intermittently for about five minutes until the chorions started to come off of the embryos. The 
embryos were then placed into a 1.5 ml tube and fixed. Fixation was performed with a solution 
of 4% paraformaldehyde. This solution was made from a stock solution of 32% 
paraformaldehyde (Electron Microscopy Sciences). Embryos were then incubated at 4°C 
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overnight or 2 hours at room temperature (25°C). Once the embryos were fixed, the 
paraformaldehyde was removed and 100% methanol was added for long term storage at -20°C. 
The embryos were then used for in situ hybridization.  
 
In situ hybridization protocol 
 In situ hybridization was performed according to a protocol from Thisse and Thisse 
(Thisse and Thisse, 2008).  
  
PCR and Gel Electrophoresis 
 PCR was done using GoTaq® (Promega). Gel electrophoresis was done according to a 
standard protocol. For most tests done, a 0.8% Gene Pure LE agarose (ISC BioExpress) gel was 
used. TAE buffer was used as a running buffer and solvent for gels. Gels were pre-cast with 
ethidium bromide and ethidium bromide was also added to the running buffer just before 
starting the gel. Gels were imaged using GelDoc (Bio-Rad) and Image Lab software (Bio-Rad). If 
needed, bands were extracted using a light box and a razor blade. The DNA was then extracted 
from the gel bands using QIAEX®II Gel Extraction Kit (Qiagen). For imaging and resolution uses, 
Metapho  ™ Lo za  aga ose as used a o di g to supplied p oto ol a d p epa ed at %. 
 
RNA extraction and cDNA synthesis 
 RNA was extracted at various embryo ages using Tri-Reagent. The Tri-Reagent-LS 
(Molecular Research Center, Inc.) supplied protocol was used for all RNA extractions. RNA was 
measured using a NanoDrop (Thermo Scientific). cDNA synthesis was done using AMV Reverse 





 All primers used were designed by author using Primer3Plus (Untergasser et al., 2007). 
Primers are shown in Table 5.1. Primers were used in all reactions at a 1:5 dilution from 100 
mM stock.  
Table 5.1 – List of primers used in PCRs. 
Target gene Forward sequence Reverse sequence 
Product 
size (bp) 
ef1α CGGTGACAACATGCTGGAGG ACCAGTCTCCACACGACCCA 220 
klf2a GCCAGAGCTATCAAGGCAAC TGCCACATCCAGAAAAAGTG 245 
klf2b (qPCR 
only) 
GAGGGCACTGTATGCTTTAC GGCTAGGTTTGAACAGTAGATG 219 
klf2b (RT-PCR 
only) 
GCCATGTATGAGGAGGCAAT CCTCCCAGTTGCAGTGGTAT 246 
klf4 CACGAAACCAACAACACCTG ACTGCTGTTGATGCGAGATG 257 




 Setting up fish: Fish were set up in one or two pairs per tank the afternoon before the 
injection date. Dividers were pulled 20-30 minutes before injections were started.  
 Injection mixes: The injection mix contains morpholinos (Gene Tools, LLC), rhodamine 
dextran dye (Molecular Probes/Invitrogen #D- , Da ieau s uffe , a d if eeded, ate . 
Final concentrations of morpholinos were as follows: 0.2mM gata2 (3rd Exon/Intron 
morpholino, seq: CATCTACTCACCAGTCTGCGCTTTG), 0.2mM gata2 mismatch (seq: 
CATCCACTCACTAGTCTACGCTGTG), 0.275mM flcnb (seq: GAGTTTTCTAATGGCCCTTACCTGC), and 
0.2mM 25-N random control oligo (seq: NNNNNNNNNNNNNNNNNNNNNNNNN). The final 
concentration of the rhodamine dextran dye is 0.025%. The final concentration of Danieau s 
buffer was 0.3X. p53 (seq: GCGCCATTGCTTTGCAAGAATTG) morpholino was added to flncb 
injections to account for toxicity (Robu et al., 2007). 
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 Injection needles: Needles were made from 1 mm thin walled borosilicate capillaries 
(World Precision Instruments, Inc.) pulled using the Sutter-97 needle puller (Sutter Instrument 
Co.) [Settings: Pressure=50 Velocity=100 Delay=200 Temperature=736]. The needles were 
broken on the day of the injection experiment. They were broken while looking through the 
microscope, breaking them into a bevel shape at a diameter that provides enough strength not 
to bend when it hits the chorion, but is thin enough to not damage a large portion of the 
embryos. The needles were loaded using 2 µl of injection mix. 
Injections: Embryos were injected with 0.524 nl of injection mix at the 1-cell stage to the 
8-cell stage. They were injected into the yolk in the opposite side from point of needle entry. 
Embryos were injected for 0.2 seconds and at 50 hPa with 15hPa as the backpressure. The 
embryos were then checked at 4-6 hpf to remove damaged, dead, unfertilized and poorly 
injected embryos. Well-injected embryos were classified as embryos that have all cells in the 
dome fluorescing the rhodamine dextran dye (red). The well-injected embryos were then 
counted and then moved forward for the remainder of the experiment. These embryos were 
stored in E3 at 28°C (with methylene blue to limit bacterial and fungal growth). Methylene blue 
was added from a 1:2000 stock (100 µl/petri dish).  
 
Microscopy and Still Images  
 All microscopy was done using an Olympus SZX12 microscope. Still images were taken 






High Speed Videos  
 Imaging Equipment: Videos were recorded with a high speed camera (Photron, 
FASTCAM SA3) mounted to a stereomicroscope (Olympus, SZX12 with SZX-AL20X lens 
attachment). Recordings were captured at 1500 frames/s (fps) in bright field lighting (Schott, 
Ace fiber optic light source 150W microscope illuminator). Photron FASTCAM Viewer software 
was used to control the camera and to save image files.  
 Image Processing: All image processing and data analysis was performed using an in-
house MATLAB interface. Image processing was done using methods from a previous lab 
member, Brennan Johnson, as described (Johnson et al., 2013a).  
 Image Analyses: Raw images were first registered by removing any artifacts from 
shaking during image acquisition and normalizing by accounting for light intensity across frames 
using a spatiotemporal (ST) plot. Image sequences were then analyzed for heart rate, diameter, 
and velocity. All other data was inferred from those three data points. Please refer to Appendix 
1 for detailed and program-specific steps on analyses. All data was provided via the MATLAB 
interface created by Johnson except for reverse flow time fractions (Johnson et al., 2013a). 
These fractions were calculated in ImageJ software (Schneider et al., 2012). Number of frames 
that contained blood moving in the reverse direction were divided by the total number of 
frames in one cycle. 
 
qPCR 
 qPCR was done with LightCycler® 480 SYBR Green I Master mix (Roche Diagnostics). 
Reactions were done in 10 µl volumes and on a 384 well plate. qPCR was analyzed using both 
absolute quantification and relative quantification methods using a standard curve. Absolute 
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quantification was presented as the log of the copy numbers per microgram of RNA. Relative 
quantification was presented as an expression ratio. Zebrafish ef1α was used as the 
endogenous control (McCurley and Callard, 2008). Data was normalized to endogenous control, 
. The normalized values were then divided by the lowest normalized value for 
select gene (or non-injected control) to obtain the expression ratio: , where 
normalizedx is any normalized value for the select target gene (or non-injected control).  
 
Statistics 
 Statistics via ANOVA were done using SigmaPlot (version 12.0) (Systat Software).  Video 
data normality was checked via Shapiro-Wilk on all means. When normality of means passed, 
e ual a ia e as tested ith Le e e s ea  test hi h as the  follo ed  a O e Wa  
ANOVA. In the event of a significant p value from the ANOVA, an all pairwise multiple 
comparison was done via Tukey test. When normality of means failed, Kruskal-Wallis One Way 
ANOVA on ranks was used. In the event of a significant p value from the ANOVA on ranks, an all 
pai ise ultiple o pa iso  as do e ia Du s ethod.   


















Ackermann GE, Paw BH. 2003. Zebrafish: A genetic model for vertebrate organogenesis and 
human disorders. Frontiers in Bioscience 8:D1227-D1253. 
Auman HJ, Coleman H, Riley HE, Olale F, Tsai H-J, Yelon D. 2007. Functional modulation of 
cardiac form through regionally confined cell shape changes. Plos Biology 5:604-615. 
Bakkers J. 2011. Zebrafish as a model to study cardiac development and human cardiac disease. 
Cardiovascular Research 91:279-288. 
Banjo T, Grajcarek J, Yoshino D, Osada H, Miyasaka KY, Kida YS, Ueki Y, Nagayama K, Kawakami 
K, Matsumoto T, Sato M, Ogura T. 2013. Haemodynamically dependent valvulogenesis 
of zebrafish heart is mediated by flow-dependent expression of miR-21. Nature 
Communications 4. 
Barrionuevo WR, Burggren WW. 1999. O-2 consumption and heart rate in developing zebrafish 
(Danio rerio): influence of temperature and ambient O-2. American Journal of 
Physiology-Regulatory Integrative and Comparative Physiology 276:R505-R513. 
Bartman T, Walsh EC, Wen KK, McKane M, Ren JH, Alexander J, Rubenstein PA, Stainier DYR. 
2004. Early myocardial function affects endocardial cushion development in zebrafish. 
Plos Biology 2:673-681. 
Bastian F, Parmentier G, Roux J, Moretti S, Laudet V, Robinson-Rechavi M. 2008. Bgee: 
Integrating and comparing heterogeneous transcriptome data among species. Data 
Integration in the Life Sciences, Proceedings 5109:124-131. 
Berdougo E, Coleman H, Lee DH, Stainier DYR, Yelon D. 2003. Mutation of weak atrium/atrial 
myosin heavy chain disrupts atrial function and influences ventricular morphogenesis in 
zebrafish. Development 130:6121-6129. 
Birely J, Schneider VA, Santana E, Dosch R, Wagner DS, Mullins MC, Granato M. 2005. Genetic 
screens for genes controlling motor nerve-muscle development and interactions. 
Developmental Biology 280:162-176. 
Boselli F, Freund JB, Vermot J. 2015. Blood flow mechanics in cardiovascular development. 
Cellular and Molecular Life Sciences 72:2545-2559. 
Bukoreshtliev NV, Haase K, Pelling AE. 2013. Mechanical cues in cellular signalling and 
communication. Cell and Tissue Research 352:77-94. 
Christen B, Robles V, Raya M, Paramonov I, Belmonte JCI. 2010. Regeneration and 
reprogramming compared. Bmc Biology 8. 
Dalman MR, Liu Q, King MD, Bagatto B, Londraville RL. 2013. Leptin expression affects 
metabolic rate in zebrafish embryos (D-rerio). Frontiers in Physiology 4. 
Davies PF. 1995. FLOW-MEDIATED ENDOTHELIAL MECHANOTRANSDUCTION. Physiological 
Reviews 75:519-560. 
Dekker RJ, van Soest S, Fontijn RD, Salamanca S, de Groot PG, VanBavel E, Pannekoek H, 
Horrevoets AJG. 2002. Prolonged fluid shear stress induces a distinct set of endothelial 
cell genes, most specifically lung Kruppel-like factor (KLF2). Blood 100:1689-1698. 
Dekker RJ, van Thienen JV, Rohlena J, de Jager SC, Elderkamp YW, Seppen J, de Vries CJM, 
Biessen EAL, van Berkel TJC, Pannekoek H, Horrevoets AJG. 2005. Endothelial KLF2 links 
85 
 
local arterial shear stress levels to the expression of vascular tone-regulating genes. 
American Journal of Pathology 167:609-618. 
Dietrich AC, Lombardo VA, Abdelilah-Seyfried S. 2014. Blood Flow and Bmp Signaling Control 
Endocardial Chamber Morphogenesis. Developmental Cell 30:367-377. 
Ekker SC, Larson JD. 2001. Morphant technology in model developmental systems. Genesis 
30:89-93. 
Fahed AC, Gelb BD, Seidman JG, Seidman CE. 2013. Genetics of congenital heart disease: the 
glass half empty (vol 112, pg 707, 2013). Circulation Research 112:E182-E182. 
Galloway JL, Wingert RA, Thisse C, Thisse B, Zon LI. 2005. Loss of Gata1 but not Gata2 converts 
erythropoiesis to myelopoiesis in zebrafish embryos. Developmental Cell 8:109-116. 
Gardiner MR, Gongora MM, Grimmond SM, Perkins AC. 2007. A global role for zebrafish klf4 in 
embryonic erythropoiesis. Mechanisms of Development 124:762-774. 
Gerety SS, Wilkinson DG. 2011. Morpholino artifacts provide pitfalls and reveal a novel role for 
pro-apoptotic genes in hindbrain boundary development. Developmental Biology 
350:279-289. 
Gijsen F, van der Giessen A, van der Steen A, Wentzel J. 2013. Shear stress and advanced 
atherosclerosis in human coronary arteries. Journal of Biomechanics 46:240-247. 
Glickman NS, Yelon D. 2002. Cardiac development in zebrafish: coordination of form and 
function. Seminars in Cell & Developmental Biology 13:507-513. 
Goishi K, Lee P, Davidson AJ, Nishi E, Zon LI, Klagsbrun M. 2003. Inhibition of zebrafish 
epidermal growth factor receptor activity results in cardiovascular defects. Mechanisms 
of Development 120:811-822. 
Grimes AC, Stadt HA, Shepherd IT, Kirby ML. 2006. Solving an enigma: Arterial pole 
development in the zebrafish heart. Developmental Biology 290:265-276. 
Groenendijk BCW, Hierck BP, Vrolijk J, Baiker M, Pourquie M, Gittenberger-de Groot AC, 
Poelmann RE. 2005. Changes in shear stress-related gene expression after 
experimentally altered venous return in the chicken embryo. Circulation Research 
96:1291-1298. 
Gu S, Jenkins MW, Peterson LM, Doughman Y-Q, Rollins AM, Watanabe M. 2012. Optical 
coherence tomography captures rapid hemodynamic responses to acute hypoxia in the 
cardiovascular system of early embryos. Developmental Dynamics 241:534-544. 
Hamik A, Lin Z, Kumar A, Balcells M, Sinha S, Katz J, Feinberg MW, Gerzsten RE, Edelman ER, 
Jain MK. 2007. Kruppel-like factor 4 regulates endothelial inflammation. Journal of 
Biological Chemistry 282:13769-13779. 
Heckel E, Boselli F, Roth S, Krudewig A, Belting HG, Charvin G, Vermot J. 2015. Oscillatory Flow 
Modulates Mechanosensitive klf2a Expression through trpv4 and trpp2 during Heart 
Valve Development. Current Biology 25:1354-1361. 
Hoage T, Ding Y, Xu X. 2012. Quantifying Cardiac Functions in Embryonic and Adult Zebrafish. 
Methods In Molecular Biology 843:11-20. 
Hogers B, DeRuiter MC, Gittenberger-de Groot AC, Poelmann RE. 1999. Extraembryonic venous 
obstructions lead to cardiovascular malformations and can be embryolethal. 
Cardiovascular Research 41:87-99. 
86 
 
Hove JR, Koster RW, Forouhar AS, Acevedo-Bolton G, Fraser SE, Gharib M. 2003. Intracardiac 
fluid forces are an essential epigenetic factor for embryonic cardiogenesis. Nature 
421:172-177. 
Howe K, Clark MD, Torroja CF, Torrance J, Berthelot C, Muffato M, Collins JE, Humphray S, 
McLaren K, Matthews L, McLaren S, Sealy I, Caccamo M, Churcher C, Scott C, Barrett JC, 
Koch R, Rauch G-J, White S, Chow W, Kilian B, Quintais LT, Guerra-Assuncao JA, Zhou Y, 
Gu Y, Yen J, Vogel J-H, Eyre T, Redmond S, Banerjee R, Chi J, Fu B, Langley E, Maguire SF, 
Laird GK, Lloyd D, Kenyon E, Donaldson S, Sehra H, Almeida-King J, Loveland J, Trevanion 
S, Jones M, Quail M, Willey D, Hunt A, Burton J, Sims S, McLay K, Plumb B, Davis J, Clee 
C, Oliver K, Clark R, Riddle C, Eliott D, Threadgold G, Harden G, Ware D, Mortimer B, 
Kerry G, Heath P, Phillimore B, Tracey A, Corby N, Dunn M, Johnson C, Wood J, Clark S, 
Pelan S, Griffiths G, Smith M, Glithero R, Howden P, Barker N, Stevens C, Harley J, Holt K, 
Panagiotidis G, Lovell J, Beasley H, Henderson C, Gordon D, Auger K, Wright D, Collins J, 
Raisen C, Dyer L, Leung K, Robertson L, Ambridge K, Leongamornlert D, McGuire S, 
Gilderthorp R, Griffiths C, Manthravadi D, Nichol S, Barker G, Whitehead S, Kay M, 
Brown J, Murnane C, Gray E, Humphries M, Sycamore N, Barker D, Saunders D, Wallis J, 
Babbage A, Hammond S, Mashreghi-Mohammadi M, Barr L, Martin S, Wray P, Ellington 
A, Matthews N, Ellwood M, Woodmansey R, Clark G, Cooper J, Tromans A, Grafham D, 
Skuce C, Pandian R, Andrews R, Harrison E, Kimberley A, Garnett J, Fosker N, Hall R, 
Garner P, Kelly D, Bird C, Palmer S, Gehring I, Berger A, Dooley CM, Ersan-Ueruen Z, Eser 
C, Geiger H, Geisler M, Karotki L, Kirn A, Konantz J, Konantz M, Oberlaender M, Rudolph-
Geiger S, Teucke M, Osoegawa K, Zhu B, Rapp A, Widaa S, Langford C, Yang F, Carter NP, 
Harrow J, Ning Z, Herrero J, Searle SMJ, Enright A, Geisler R, Plasterk RHA, Lee C, 
Westerfield M, de Jong PJ, Zon LI, Postlethwait JH, Nuesslein-Volhard C, Hubbard TJP, 
Crollius HR, Rogers J, Stemple DL. 2013. The zebrafish reference genome sequence and 
its relationship to the human genome. Nature 496:498-503. 
Jaalouk DE, Lammerding J. 2009. Mechanotransduction gone awry. Nature Reviews Molecular 
Cell Biology 10:63-73. 
Jamison RA, Samarage CR, Bryson-Richardson RJ, Fouras A. 2013. In Vivo Wall Shear 
Measurements within the Developing Zebrafish Heart. Plos One 8. 
Johnson BM, Garrity DM, Dasi LP. 2013a. Quantifying Function in the Early Embryonic Heart. 
Journal of Biomechanical Engineering-Transactions of the Asme 135. 
Johnson BM, Garrity DM, Dasi LP. 2013b. The Transitional Cardiac Pumping Mechanics in the 
Embryonic Heart Cardiovascular Engineering and Technology. 
Just S, Berger IM, Meder B, Backs J, Keller A, Marquart S, Frese K, Patzel E, Rauch G-J, Katus HA, 
Rottbauer W. 2011. Protein Kinase D2 Controls Cardiac Valve Formation in Zebrafish by 
Regulating Histone Deacetylase 5 Activity. Circulation 124:324-U157. 
Kalluri R, Weinberg RA. 2009. The basics of epithelial-mesenchymal transition. Journal of 
Clinical Investigation 119:1420-1428. 
Kimmel CB, Ballard WW, Kimmel SR, Ullmann B, Schilling TF. 1995. STAGES OF EMBRYONIC-
DEVELOPMENT OF THE ZEBRAFISH. Developmental Dynamics 203:253-310. 
Kopp R, Schwerte T, Egg M, Sandbichler AM, Egger B, Pelster B. 2010. Chronic reduction in 
cardiac output induces hypoxic signaling in larval zebrafish even at a time when 
convective oxygen transport is not required. Physiological Genomics 42A:8-23. 
87 
 
Kotkamp K, Moessner R, Allen A, Onichtchouk D, Drieyer W. 2014. A Pou5f1/Oct4 dependent 
Klf2a, Klf2b, and Klf17 regulatory sub-network contributes to EVL and ectoderm 
development during zebrafish embryogenesis. Developmental Biology 385:433-447. 
Kowalski WJ, Dur O, Wang Y, Patrick MJ, Tinney JP, Keller BB, Pekkan K. 2013. Critical 
Transitions in Early Embryonic Aortic Arch Patterning and Hemodynamics. Plos One 8. 
Lee J, Moghadam ME, Kung E, Cao H, Beebe T, Miller Y, Roman BL, Lien C-L, Chi NC, Marsden 
AL, Hsiai TK. 2013. Moving Domain Computational Fluid Dynamics to Interface with an 
Embryonic Model of Cardiac Morphogenesis. Plos One 8. 
Lee JS, Yu C, Shin JT, Sebzda E, Bertozzi C, Chen M, Mericko P, Stadtfeld M, Zhou D, Cheng L, 
Graf T, MacRae CA, Lepore JJ, Lo CW, Kahn ML. 2006. KIf2 is an essential regulator of 
vascular hemodynamic forces in vivo. Developmental Cell 11:845-857. 
Lin Y-F, Swinburne I, Yelon D. 2012. Multiple influences of blood flow on cardiomyocyte 
hypertrophy in the embryonic zebrafish heart. Developmental Biology 362:242-253. 
Lin YY. 2012. Muscle diseases in the zebrafish. Neuromuscular Disorders 22:673-684. 
Martinsen BJ. 2005. Reference guide to the stages of chick heart embryology. Developmental 
Dynamics 233:1217-1237. 
McCurley AT, Callard GV. 2008. Characterization of housekeeping genes in zebrafish: male-
female differences and effects of tissue type, developmental stage and chemical 
treatment. Bmc Molecular Biology 9. 
Meyer A, Schartl M. 1999. Gene and genome duplications in vertebrates: the one-to-four (-to-
eight in fish) rule and the evolution of novel gene functions. Current Opinion in Cell 
Biology 11:699-704. 
Miyasaka KY, Kida YS, Banjo T, Ueki Y, Nagayama K, Matsumoto T, Sato M, Ogura T. 2011. 
Heartbeat regulates cardiogenesis by suppressing retinoic acid signaling via expression 
of miR-143. Mechanisms of Development 128:18-28. 
Nagai R, Friedman SL, Kasuga M, editors. The Biology of Krüppel-like Factors. Springer. 
Nagai R, Friedman SL, Kasuga M. 2009. The Biology of Krüppel-like Factors. Springer. 
Oates AC, Pratt SJ, Vail B, Yan YL, Ho RK, Johnson SL, Postlethwait JH, Zon LI. 2001. The zebrafish 
klf gene family. Blood 98:1792-1801. 
Parker T, Libourel P-A, Hetheridge MJ, Cumming RI, Sutcliffe TP, Goonesinghe AC, Ball JS, Owen 
SF, Chomis Y, Winter MJ. 2014. A multi-endpoint in vivo larval zebrafish (Danio rerio) 
model for the assessment of integrated cardiovascular function. Journal of 
Pharmacological and Toxicological Methods 69:30-38. 
Parmar KM, Larman HB, Dai GH, Zhang YH, Wang ET, Moorthy SN, Kratz JR, Lin ZY, Jain MK, 
Gimbrone MA, Garcia-Cardena G. 2006. Integration of flow-dependent endothelial 
phenotypes by Kruppel-like factor 2. Journal of Clinical Investigation 116:49-58. 
Piekarski K, Munro M. 1977. TRANSPORT MECHANISM OPERATING BETWEEN BLOOD-SUPPLY 
AND OSTEOCYTES IN LONG BONES. Nature 269:80-82. 
Pierpont ME, Basson CT, Benson DW, Jr., Gelb BD, Giglia TM, Goldmuntz E, McGee G, Sable CA, 
Srivastava D, Webb CL. 2007. Genetic basis for congenital heart defects: Current 
knowledge - A scientific statement from the American heart association congenital 




Renz M, Otten C, Faurobert E, Rudolph F, Zhu Y, Boulday G, Duchene J, Mickoleit M, Dietrich AC, 
Ramspacher C, Steed E, Manet-Dupe S, Benz A, Hassel D, Vermot J, Huisken J, Tournier-
Lasserve E, Felbor U, Sure U, Albiges-Rizo C, Abdelilah-Seyfried S. 2015. Regulation of 
beta 1 Integrin-Klf2-Mediated Angiogenesis by CCM Proteins. Developmental Cell 
32:181-190. 
Robu ME, Larson JD, Nasevicius A, Beiraghi S, Brenner C, Farber SA, Ekker SC. 2007. p53 
activation by knockdown technologies. Plos Genetics 3:787-801. 
Rosa N, Simoes R, Magalhaes FD, Marques AT. 2015. From mechanical stimulus to bone 
formation: A review. Medical Engineering & Physics 37:719-728. 
Ruparelia AA, Zhao M, Currie PD, Bryson-Richardson RJ. 2012. Characterization and 
investigation of zebrafish models of filamin-related myofibrillar myopathy. Human 
Molecular Genetics 21:4073-4083. 
Santhanakrishnan A, Miller LA. 2011. Fluid Dynamics of Heart Development. Cell Biochemistry 
and Biophysics 61:1-22. 
Schneider CA, Rasband WS, Eliceiri KW. 2012. NIH Image to ImageJ: 25 years of image analysis. 
Nature Methods 9:671-675. 
Schwerte T. 2009. Cardio-respiratory control during early development in the model animal 
zebrafish. Acta Histochemica 111:230-243. 
Sidi S, Rosa FM. 2004. Mechanotransduction of hemodynamic forces regulates organogenesis. 
M S-Medecine Sciences 20:557-561. 
Stainier DYR, Weinstein BM, Detrich HW, Zon LI, Fishman MC. 1995. CLOCHE, AN EARLY ACTING 
ZEBRAFISH GENE, IS REQUIRED BY BOTH THE ENDOTHELIAL AND HEMATOPOIETIC 
LINEAGES. Development 121:3141-3150. 
Staudt D, Stainier D. 2012. Uncovering the Molecular and Cellular Mechanisms of Heart 
Development Using the Zebrafish. Annual Review of Genetics, Vol 46 46:397-418. 
Taber LA, Eggers DW. 1996. Theoretical study of stress-modulated growth in the aorta. Journal 
of Theoretical Biology 180:343-357. 
Taber LA, Ng S, Quesnel AM, Whatman J, Carmen CJ. 2001. Investigating Murray's law in the 
chick embryo. Journal of Biomechanics 34:121-124. 
Thisse B, Christine. 2004. Fast Release Clones: A High Throughput Expression Analysis. ZFIN 
Direct Data Submission. In. 
Thisse B, SophieFurthauer, MaximilianLoppin, BenjaminHeyer, VincentDegrave, AgnesWoehl, 
RoxaneLux, ASteffan, TaniaCharbonnier, X. Q.Thisse, Christine. 2001. Expression of the 
zebrafish genome during embryogenesis (NIH R01 RR15402). ZFIN Direct Data 
Submission. In. 
Thisse C, Thisse B. 2008. High-resolution in situ hybridization to whole-mount zebrafish 
embryos. Nature Protocols 3:59-69. 
Thompson TG, Chan YM, Hack AA, Brosius M, Rajala M, Lidov HGW, McNally EM, Watkins S, 
Kunkel LM. 2000. Filamin 2 (FLN2): A muscle-specific sarcoglycan interacting protein. 
Journal of Cell Biology 148:115-126. 
Tobita K, Garrison JB, Liu LJ, Tinney JP, Keller BB. 2005. Three-dimensional myofiber 
architecture of the embryonic left ventricle during normal development and altered 
mechanical loads. Anatomical Record Part a-Discoveries in Molecular Cellular and 
Evolutionary Biology 283A:193-201. 
89 
 
Tu S, Chi NC. 2012. Zebrafish models in cardiac development and congenital heart birth defects. 
Differentiation 84. 
Untergasser A, Nijveen H, Rao X, Bisseling T, Geurts R, Leunissen JAM. 2007. Primer3Plus, an 
enhanced web interface to Primer3. Nucleic Acids Research 35:W71-W74. 
Valdes-Mas R, Gutierrez-Fernandez A, Gomez J, Coto E, Astudillo A, Puente DA, Reguero JR, 
Alvarez V, Moris C, Leon D, Martin M, Puente XS, Lopez-Otin C. 2014. Mutations in 
filamin C cause a new form of familial hypertrophic cardiomyopathy. Nature 
Communications 5. 
Van der Velde ET, Vriend JWJ, Mannens M, Uiterwaal C, Brand R, Mulder BJM. 2005. CONCOR, 
an initiative towards a national registry and DNA-bank of patients with congenital heart 
disease in the Netherlands: Rationale, design, and first results. European Journal of 
Epidemiology 20:549-557. 
Verbruggen SW, Vaughan TJ, McNamara LM. 2014. Fluid flow in the osteocyte mechanical 
environment: a fluid-structure interaction approach. Biomechanics and Modeling in 
Mechanobiology 13:85-97. 
Vermot J, Forouhar AS, Liebling M, Wu D, Plummer D, Gharib M, Fraser SE. 2009. Reversing 
Blood Flows Act through klf2a to Ensure Normal Valvulogenesis in the Developing Heart. 
Plos Biology 7. 
Wang L, Zhang P, Wei Y, Gao Y, Patient R, Liu F. 2011. A blood flow-dependent klf2a-NO 
signaling cascade is required for stabilization of hematopoietic stem cell programming in 
zebrafish embryos. Blood 118:4102-4110. 
Yelon D. 2001. Cardiac patterning and morphogenesis in zebrafish. Developmental Dynamics 
222:552-563. 
Yelon D, Ticho B, Halpern ME, Ruvinsky I, Ho RK, Silver LM, Stainier DYR. 2000. The bHLH 
transcription factor Hand2 plays parallel roles in zebrafish heart and pectoral fin 
development. Development 127:2573-2582. 
Yokoi H, Yan Y-L, Miller MR, BreMiller RA, Catchen JM, Johnson EA, Postlethwait JH. 2009. 
Expression profiling of zebrafish sox9 mutants reveals that Sox9 is required for retinal 
differentiation. Developmental Biology 329:1-15. 
Zhou ZN, Rawnsley DR, Goddard LM, Pan W, Cao XJ, Jakus Z, Zheng H, Yang JS, Arthur JSC, 
Whitehead KJ, Li DA, Zhou B, Garcia BA, Zheng XJ, Kahn ML. 2015. The Cerebral 
Cavernous Malformation Pathway Controls Cardiac Development via Regulation of 


















Using the MATLAB KAT interface. 
 Registering and Normalizing Image Sequences 
1. Che k the A“  he k o  A“ = A ti-shake). 
2. Cli k Ope  “e ue e . 
3. Choose the fi st file i  the se ue e a d li k Ope . This ill load i  the fi st 
image. There will be a blue rectangle around the whole image and a green rectangle 
in the middle. 
4. Use the blue rectangle to specify the area of the image you want to keep 
5. Place the green rectangle in a static part of the image (not somewhere that the 
heart will overlap at any point in the cycle). Make sure there are high-contrast 
features present within the green box (cells on the chest or pigmentation are usually 
a good option). The green box is the template box used to align all images in the 
sequence. The green box does not have to be within the blue box.  
6. Cli k Ope  “e ue e . The o pute  ill atte pt to e o e all a e a shake 
present (i.e. register the image) and will crop the image as specified. 
7. Cli k Ne  ‘L . D a  a efe e e li e i  a g a  pa t of the i age hi h does ot 
overlap the heart. Avoid very dark or very light parts of the image. This will be used 
to normalize the lighting, which will remove electricity-based lighting fluctuations. 
91 
 
8. Cli k “T Plot . If the e a e lighti g flu tuatio s, the e ill e e ti al a di g i  the 
ST plot. 
9. Cli k No alize Light . This ill fi  the flu tuatio s. 
10. Cli k E po t F a es  a d hoose a  app op iate folde  a d ase file name. This will 
save the entire normalized image sequence.  
Analyzing Heart Function 
1. Lea e the A“  he k o  u he ked. 
2. Cli k Ope  “e ue e . 
3. Choose the fi st file i  ou  NO‘MALI)ED se ue e a d li k Ope . This ill load 
in the first image. You have the option of cropping the image, but if everything is 
egiste ed/ o alized, the  do t op it. 
4. Cli k Ope  “e ue e  agai . This ill load i  the est of the i ages. 
HEART RATE 
5. Cli k Ne  ‘L  
6. Draw a new reference line on the image. Position it so that the edge of the heart 
overlaps the line, but make sure that the line is not in an area of prominent blood 




7. Cli k “T Plot , esulti g plot should ese le i age elo . 
 
8. Cli k Cal  H‘ . Patte  should alig  a d a li e g aph ill pop up ith a sha p 
negative peak.  
a. If pattern is not aligning, you can go to Fr/Cyc and manipulate the number to 





9. Cli k Ne  ‘L . 
10. Draw a new reference line which goes across the orifice of choice, perpendicular to 
the di e tio  of lood flo . O e li e is pla ed, li k “et KF  ke  f a e , so the 
reference line can move as the orifice moves. Click the arrow to move through 
frames, and at each frame throughout a cycle that the AVJ seems to either change in 
speed and/or direction, adjust the position of the reference line over the AVJ and 
li k “et KF.  ‘epeat this u til the e d of the le.  As the e d of the le 
approaches, the reference line should start to automatically position itself correctly.   
11. Cli k “T Plot . 
12. Cli k “a e ‘L . Choose a folde  to sa e it i . This folde  ill e also e holdi g othe  
files related to the analysis of this image sequence. The beginning of the file name is 
set by default. I e o e d addi g a D  to the e d i  o de  to spe if  that this is 
the Diameter reference line. 
13. Cli k Measu e D . This ope s a e  fo  KATD . 
14. Choose the u e  of poi ts to o k ith a d li k Update .  is e o e ded.  
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a. At this point you can also choose si gle le  to o k ith i di idual les. 
This can sometimes make it easier to plot points. 
15. Cli k Edit Poi ts . Positio  the poi ts so that the  follo  the edges of the flo  
boundary. To set a point in a new location, click near it. The point will turn red. Click 
in a new location to set it somewhere else. Repeat for all points. Press Ctrl+c to exit 
the point-editing mode. 
a. NOTE: If steps are not followed closely in this, errors will occur and the entire 
process must be started over (starting with uploading and heart rate).  
Simply clicking outside of the ST plot when picking points can cause errors. 
 
16. When you are satisfied with their position, increase the number of points and click 
Update . This ill add poi ts hi h a e li ea l  i te polated etween the other 
points you have set. You can verify that the points look to be in an accurate pattern. 
17. Refine the position of the points along the flow boundary, if needed. When 
everything is set, close the form. Points are saved automatically. 
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18. Checking the “ho  D Pts  he k o  ill displa  dots o  the efe e e li e 
corresponding to where the flow width was measured. You can then play back 
through the sequence to ensure that the point placement is accurate. 
a. NOTE: The D pts will not show up on the reference line if it moves around 
using key frames.  There is an error in the display that causes it to position 
along some invisible static line.  You will just have to pause the video at 
random points to make sure that the dots look the same distance apart as 
the AVJ diameter. 
VELOCITY   
19. Cli k Ne  ‘L . 
20. Draw a reference line which runs parallel to the direction of blood flow, and which is 
centered over the diameter reference line. Once placed, the diameter reference line 




21. Go forward and backward in the sequence as needed to determine exactly which 
angle the reference line should be positioned on the first frame. Once satisfied that 
it is parallel to the blood flow on the first frame, cli k “et KF . 
a. NOTE: Make sure a key frame is set on the first frame! Otherwise it will not 
interpolate the position of the reference line between the last key frame to 
the position on the next cycle.  
22. Click ahead into the image sequence. The direction of flow will likely change. At 
some point, the reference line will not be aligned with the flow. You will be resetting 
its location at various key frames throughout the sequence. Its position will then be 
linearly interpolated between each key frame. If you understand this point, it should 
be easy to intelligently choose where to place key frames such that the reference 
line stays accurate. You should be able to pull this off with about 5 key frames. There 
is t a lot of elo it  e o  asso iated ith i o  ariations in reference line angle vs. 
blood flow direction.  
23. O e all ke  f a es ha e ee  set, li k “a e ‘L . Choose a folde  to sa e it i . The 
egi i g of the file a e is set  default. I e o e d addi g a V  to the e d i  
order to specify that this is the Velocity reference line. 
24. Cli k Cal  Vel. . The o pute  ill go th ough its auto-calculation of velocity for 
each frame. 
25. Whe  the a al sis is fi ished, li k “a e All . Do ot ha ge the default a e! It 
will save multiple files based on this name and you can goof everything up if you 
ha ge it. Just li k “a e  afte  ou ha e ou o e t file lo atio  pi ked. 
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26. Cli k A al ze ‘esults . This ope s a e  fo  KATA . All of the a  esults ill e 
displayed. 
27. You will almost certainly need to threshold the data to remove junk data points. 
Choose the Th eshold Data  optio  o  the otto  left. Keep adjusti g the 
a / ea  u e  u til the data looks as lea  a d a u ate as possi le. The e 
should be few if any outliers. 
a. You a  also li k o  C le a e aged  a d adjust a / ea  that a  as 
well.  
28. If ou a e op i g the data i to a sp eadsheet, I e o e d li ki g the “u a  
Lo g  optio , the  li ki g Cop  Data Col . This opies all of the esults i  the 
form of a single column of data. This is convenient for analysis and plotting in Excel. 







First Fr 3 
Last Fr 3268 
fr/bin 25 
Bin incr 5 
fr/cyc  514 
# Cycles 6 
Threshold 4.1 
  
HR (bpm) 175.1 
SV (nL) 0.05 
CO (nL/min) 8.8 
RF 0 
Vmax (mm/s) 13.62 
Vmean (mm/s) 4.9 
  











































































































Dia (um)  










































































































Q (nL/min)  








































































































AccVol (nL)  










































































































NORMALIZING AND ORGANIZING DATA 
When data is ready for more than one embryo, you will need to align data so the 
cycles align. An example Excel sheet has been placed on the lab computer.  
DIAMETER 
30. Fi d a  alue i  all datasets fo  dia ete . Usi g the = a  fu tio .  
31. Grab max values and all data underneath and move to new column. (For each 
dataset individually) 
32. Then grab the rest of the data and place it underneath its respective new column. 
Now all diameters should be arranged with max at top.  
33. Now you want to make the max be in the middle of the dataset, grab the lower half 
of the data square you currently have and place it at the top of new columns.  
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34. Then grab the top of the data set (max should be at top) and move it underneath. 
Max should now be in the middle. (placed at time 0.5050) 
35. To normalize data, divide each value in a column by its respective max value. This is 
your normalized diameter.  
VELOCITY 
36. Repeat max value organizing steps as described under diameter.  
37. Now divide each value in a column by the max diameter in mm. (NOTE that your 
current diameter is in µm.) 
38. Then divide this new value by the heart rate in seconds. (Current heart rate is in 
beats per minute, you will need to convert to beats per second.) This is your 
normalized velocity. 
Q - Flow 
39. Repeat max value organizing steps as described under diameter. 
40. First you need to convert to m3/min. This is done by multiplying each value by 1012.  
41. Then you need to convert to m3/s. This is done by dividing each value by 60.  
42. Next, normalize to give units 1/s. You will divide each value by max diameter in mm3. 
(You will need to convert this from your max diameter values.) 
43. Last step is to normalize time to make dimensionless. Divide each value by heart rate 
in seconds. This is your normalized flow rate.  
